UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

| ın | re: | | | |
|----|-----|--|--|--|
| | | | | |

Debtors.1

PURDUE PHARMA L.P., et al.,

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered) Objection Deadline: March 9, 2021 at 5:00 p.m. ET

SIXTEENTH MONTHLY FEE APPLICATION OF DECHERT LLP FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES AS COUNSEL TO THE DEBTORS AND DEBTORS IN POSSESSION FOR THE PERIOD FROM DECEMBER 1, 2020 THROUGH DECEMBER 31, 2020

| Name of Applicant: | Dechert LLP |
|--|----------------------------------|
| Authorized to Provide Professional Services to: | Purdue Debtors and |
| | Debtors in Possession |
| Effective Date of Retention: | November 21, 2019 |
| | Nunc Pro Tunc to |
| | September 15, 2019 |
| Period for which compensation and | December 1, 2020 |
| reimbursement is sought: | through December 31, |
| | 2020 |
| Amount of compensation sought as actual, reasonable, and | |
| necessary: | \$649,713.26 ² |
| Eighty percent of actual, reasonable and necessary compensation: | \$519,770.61 |
| Amount of expense reimbursement sought as actual, reasonable, | \$94,493.85 |
| and necessary: | |

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

This amount reflects a reduction in fees in the amount of \$153,999.74 on account of voluntary discounts for aggregate fees as described in the *Application of Debtors for Authority to Retain and Employ Dechert LLP as Special Counsel to the Debtors* Nunc Pro Tunc *to the Petition Date* [Docket No. 424] (the "**Retention Application**") and *Dechert LLP's First Notice of Increase in Hourly Rates for Patent Services* [Docket No. 965] (the "**Notice of Increased Patent Fees**").

| This is $a(n)$: | <u>X</u> Monthly | Interim | Final application. |
|-------------------|----------------------|---------|--------------------|
| Is this the first | monthly application? | Yes | _X_No |

This application includes 70.1 hours with a value of \$26,895.50 incurred in connection with the preparation of Fee Applications for the Debtors.

Compensation by Individual for Debtors for Litigation Services

| Name of Professional Person | Position of the Applicant | Year of Obtaining License to Practice (if Applicable) | Hourly Billing Rate (Including Changes) ³ | Total Billed Hours | Total Compensation |
|----------------------------------|---------------------------|---|--|--------------------------|-----------------------|
| Sheila L Birnbaum | Partner | 1965 | 1,350.00 | 144.90 | 195,615.00 |
| Hayden A. Coleman | Partner | 1985 | 915.00 | 122.00 | 111,630.00 |
| Hope S. Freiwald | Partner | 1980 | 1,090.00 | 17.00 | 18,530.00 |
| Mara C. Cusker Gonzalez | Partner | 2005 | 890.00 | 13.60 | 12,444.00 |
| Paul A. LaFata | Partner | 2007 | 890.00 | 17.80 | 15,842.00 |
| Sara B. Roitman | Partner | 2010 | 890.00 | 78.90 | 72,193.50 |
| Erik W. Snapp | Partner | 1995 | 915.00 | 0.50 | 457.50 |
| Jonathan S. Tam | Partner | 2009 | 890.00 | 13.50 | 12,015.00 |
| Shmuel Vasser | Partner | 1988 | 915.00 | 24.00 | 21,960.00 |
| Bert L. Wolff | Partner | 1981 | 915.00 | 0.30 | 274.50 |
| Christopher R. Boisvert | Counsel | 2009 | 890.00 | 82.60 | 73,514.00 |
| Danielle Gentin Stock | Counsel | 1999 | 890.00 | 90.50 | 80,545.00 |
| Michelle K. Yeary | Counsel | 1995 | 890.00 | 59.70 | 53,133.00 |
| Alyssa C. Clark | Associate | 2017 | 725.00 | 1.80 | 1,305.00 |
| Sarah Magen | Associate | 2012 | 855.00 | 48.20 | 41,211.00 |
| Jenna C. Newmark | Associate | 2011 | 855.00 | 22.10 | 18,895.50 |
| Katherine Norman | Associate | 2019 | 565.00 | 5.50 | 3,107.50 |
| Lindsay N. Zanello | Associate | 2015 | 800.00 | 1.40 | 1,120.00 |
| Nicholas C. Dean | Staff Attorney | | 365.00 | 0.50 | 182.50 |
| Antonella Capobianco- Ranallo | Legal Asst | N/A | 200.00 | 3.50 | 700.00 |
| Jefferson Holder | Legal Asst | N/A | 200.00 | 0.40 | 80.00 |
| Matthew B. Stone | Legal Asst | N/A | 200.00 | 49.70 | 9,940.00 |

As described in the Retention Application, these billing rates reflect voluntary discounts of 1% to 24% for senior partners, 6% to 13% for junior partners, 1% to 5% for counsel, and 5% to 10% for associates.

| Denise Neris | Project Asst | N/A | 155.00 | 12.50 | 1,937.50 |
|-------------------------|--------------|-----|--------|--------|----------------|
| Total | | | | 811.90 | \$747,522.50 |
| 20% Volume Discount | | | | | (\$149,504.50) |
| Discounted Total | | | | | \$598,018.00 |
| Total Amount | | | | | |
| Requested Herein | | | | | \$478,414.40 |

Compensation by Individual for Debtors for Patent Services

| Name of Professional Person | Position of the Applicant | Year of Obtaining License to Practice (if Applicable) | Hourly Billing Rate (Including Changes) ⁴ | Total Billed Hours | Total Compensation |
|----------------------------------|---------------------------|---|---|--------------------------|-----------------------|
| Samuel B. Abrams | Partner | 1981 | 885.00 | 23.10 | 20,443.50 |
| Blaine M. Hackman | Associate | 2012 | 740.00 | 17.70 | 13,098.00 |
| Seth E. Snyder | Patent Agent | | 585.00 | 30.90 | 18,076.50 |
| Sherrice T. Breland | Legal Assistant | N/A | 285.00 | 15.70 | 4,474.50 |
| Erin K. Peacock | Legal Assistant | N/A | 245.00 | 0.40 | 98.00 |
| Total | | | | 87.80 | \$56,190.50 |
| 8% Volume Discount ⁵ | | | | | (\$4,495.24) |
| Discounted Total | | | | | \$51,695.26 |
| Total Amount Requested Herein | | | | | \$41,356.21 |

The blended hourly billing rate of professionals for all services provided during the Fee Period is \$722.14.

⁴ As described in Notice of Increased Patent Fees, these billing rates reflect voluntary discounts of 10% to 28% for partners, 19% for counsel, 22% for associates, 0% to 18% for paraprofessionals, and 7% to 10% for patent agents.

As described in the Notice of Increased Patent Fees, Dechert will apply an 8% discount for aggregate fees and this aggregate discount will apply to all timekeepers.

Compensation by Project Category for Debtors

| Code | Project Category | Total Hours | Total Fees |
|-------|---|--------------------|----------------------|
| B110 | Case Administration | 0.60 | \$334.50 |
| B160 | Fee/Employment Applications | 70.10 | \$26,895.50 |
| B165 | Budgeting (case) | 1.00 | \$915.00 |
| B310 | Claims Administration and Objections | 2.70 | \$2,470.50 |
| L120 | Analysis/Strategy | 171.50 | \$172,070.50 |
| L130 | Experts/Consultants | 46.00 | \$41,709.00 |
| L150 | Budgeting | 0.20 | \$178.00 |
| L160 | Settlement/Non-Binding ADR | 103.60 | \$122,615.50 |
| L190 | Other Case Assessment, Development and Administration | 14.40 | \$2,317.50 |
| L210 | Pleadings | 82.80 | \$84,525.50 |
| L220 | Preliminary Injunctions/Provisional Remedies | 7.70 | \$6,853.00 |
| L230 | Court Mandated Conferences | 3.50 | \$3,842.50 |
| L310 | Written Discovery | 20.50 | \$19,863.00 |
| L320 | Document Production | 184.70 | \$166,204.50 |
| L330 | Depositions | 4.20 | \$3,843.00 |
| L350 | Discovery Motions | 2.20 | \$2,970.00 |
| L390 | Other Discovery | 2.30 | \$2,104.50 |
| L410 | Fact Witnesses | 74.40 | \$68,586.00 |
| L440 | Other Trial Preparation and Support | 6.80 | \$6,052.00 |
| L450 | Trial and Hearing Attendance | 12.30 | \$12,816.50 |
| L520 | Appellate Briefs | 0.40 | \$356.00 |
| P260 | Intellectual Property | 87.80 | \$56,190.50 |
| T | | 000.70 | 4002 2 42 224 |
| Total | | 899.70 | \$803,713.006 |

⁶ This amount reflects the discounted billing rates but not the discounts for aggregate fees.

Expense Summary for Debtors

| Expenses Category | Total Expenses |
|-------------------------------|-------------------|
| Consultants Fees ⁷ | \$88,723.47 |
| Court Costs | \$210.00 |
| Filing Fees and Related | \$5,519.00 |
| Taxi Fare | \$41.38 |
| | |
| Total | \$94,493.85 |

These consultant fees are Ankura Consulting Group, LLC, a firm that manages a document hosting platform necessary for Dechert to provide legal services to the Debtors.

| UNITED STATES BANKRUPTCY COUL | X T |
|-------------------------------|------------|
| SOUTHERN DISTRICT OF NEW YORK | |

In re:

PURDUE PHARMA L.P., et al.,

Debtors.1

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered) Objection Deadline: March 9, 2021 at 5:00 p.m. ET

SIXTEENTH MONTHLY FEE APPLICATION OF DECHERT LLP FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES AS COUNSEL TO THE DEBTORS AND DEBTORS IN POSSESSION FOR THE PERIOD FROM DECEMBER 1, 2020 THROUGH DECEMBER 31, 2020

By this monthly fee application (the "Application"), pursuant to sections 330 and 331 of title 11 of the United States Code (the "Bankruptcy Code") and Rule 2016 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), Dechert LLP ("Dechert") hereby moves this Court for discounted reasonable compensation for professional legal services rendered as attorneys to the Debtors in the amount of \$519,770.61 together with reimbursement for actual and necessary expenses incurred in the amount of \$94,493.85, for the period commencing December 1, 2020 through and including December 31, 2020 (the "Fee Period"). In support of the Application, Dechert respectfully represents as follows:

Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove

- 1. Dechert was employed under a general retainer to represent the Debtors as bankruptcy counsel in connection with these chapter 11 cases pursuant to an order entered by this Court on November 21, 2019 [Docket No. 525] (the "Retention Order"). The Retention Order authorized Dechert to be compensated on an hourly basis and to be reimbursed for actual and necessary out-of-pocket expenses.
- 2. All services for which compensation is requested by Dechert were performed for or on behalf of the Debtors.

SUMMARY OF SERVICES RENDERED

- 3. Attached hereto as **Exhibit A** is a detailed statement of fees incurred during the Fee Period showing the amount of \$649,713.26,² of which \$519,770.61 is requested for fees in this Application. **Exhibit B** is a detailed statement of expenses paid during the Fee Period showing the amount of \$94,493.85 for reimbursement of expenses.
- 4. The services rendered by Dechert during the Fee Period are grouped into the categories set forth in **Exhibit A**. The attorneys and paralegals who rendered services relating to each category are identified, along with the number of hours for each individual and the total compensation sought for each category, in the attachments hereto.

DISBURSEMENTS

5. Dechert has incurred out-of-pocket disbursements during the Fee Period in the amount of \$94,493.85. This disbursement sum is broken down into categories of charges, including, among other things, document hosting and management, temporary employee

This amount reflects a reduction in fees in the amount of \$153,999.74 on account of voluntary discounts for aggregate fees as described in the *Application of Debtors for Authority to Retain and Employ Dechert LLP as Special Counsel to the Debtors* Nunc Pro Tunc *to the Petition Date* [Docket No. 424] (the "**Retention Application**") and *Dechert LLP's First Notice of Increase in Hourly Rates for Patent Services* [Docket No. 965] (the "**Notice of Increased Patent Fees**").

expenses, expert consulting charges, telephone and telecopier toll and other charges, mail and express mail charges, special or hand delivery charges, document processing, photocopying charges, charges for mailing supplies (including, without limitation, envelopes and labels) provided by Dechert to outside copying services for use in mass mailings, travel expenses, expenses for "working meals," computerized research, and transcription costs.

- 6. A complete review of the expenses incurred for the Fee Period may be found in the attachments hereto as **Exhibit B**. To the extent such itemization is insufficient to satisfy the requirements of Rule 2016-1(a) of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the Southern District of New York (the "**Local Rules**"), Dechert respectfully requests that the Court waive strict compliance with such rule.
- 7. Costs incurred for computer assisted research are not included in Dechert's normal hourly billing rates and, therefore, are itemized and included in Dechert's disbursements. Pursuant to Local Rule 2016-1, Dechert represents that its rate for duplication is \$.10 per page, there is no charge for incoming or outgoing telecopier transmissions, and there is no surcharge for computerized research.

VALUATION OF SERVICES

- 8. Attorneys and paraprofessionals of Dechert have expended a total of 899.7 hours in connection with the Debtors' chapter 11 cases during the Fee Period.
- 9. The amount of time spent by each of these persons providing services to the Debtors for the Fee Period is fully set forth in detail in **Exhibit A**. These are Dechert's discounted hourly rates for compensation in this case, as reflected in the Retention Application. The Discounted value of the services rendered by Dechert for the Fee Period as counsel for the

Debtors in these cases under chapter 11 is \$649,713.26, of which \$519,770.61 is requested for fees in this Application.

- 10. Dechert believes that the time entries included in **Exhibit A** attached hereto and the expense breakdown set forth in **Exhibit B** attached hereto are in compliance with the requirements of Local Rule 2016-1.
- 11. In accordance with the factors enumerated in section 330 of the Bankruptcy Code, the amount requested is fair and reasonable given (a) the complexity of this case, (b) the time expended, (c) the nature and extent of the services rendered, (d) the value of such services, and (e) the costs of comparable services other than in a case under this title.
- 12. This Application covers the period of December 1, 2020 through and including December 31, 2020 with respect to the Debtors. Dechert has and will continue to perform additional necessary services for the Debtors subsequent to December 31, 2020, for which Dechert will file subsequent fee applications.

[Remainder of page left intentionally blank]

CONCLUSION

WHEREFORE, Dechert respectfully requests that (a) allowance be made to it in the sum of \$519,770.61 as compensation for necessary professional services rendered to the Debtors for the Fee Period, and the sum of \$94,493.85 for reimbursement of actual necessary costs and expenses incurred during the Fee Period, (b) such other further relief as this Court may deem just and proper.

Dated: February 23, 2021 Respectfully submitted,

/s/ Shmuel Vasser

Shmuel Vasser DECHERT LLP

1095 Avenue of the Americas New York, New York 10036 Telephone: (212) 698-3500

Facsimile: (212) 698-3599

Attorneys for Debtors and Debtors in Possession

19-23649-shl Doc 2412 Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 11 of 107

| UNITED STATES BANKRUPTCY COURT |
|--------------------------------|
| SOUTHERN DISTRICT OF NEW YORK |

In re: Chapter 11

PURDUE PHARMA L.P., et al.,

Debtors.1

Case No. 19-23649 (RDD)
(Jointly Administered)

VERIFICATION OF SHMUEL VASSER

- I, Shmuel Vasser, Esquire, hereby declare the following under penalty of perjury:
- 1. I am a Partner in the applicant firm, Dechert LLP, and have been admitted to the bar of New York since 1991.
- 2. I have personally performed some of the legal services rendered by Dechert LLP as counsel for the Debtors, and I am generally familiar with all other work performed on behalf of the Debtors by the lawyers and paraprofessionals in the firm.
- 3. The facts set forth in the foregoing Application are true and correct to the best of my knowledge, information and belief.

[Remainder of page left intentionally blank]

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

4. I hereby certify under 28 U.S.C. § 1746 that the foregoing is true and correct to the best of my knowledge, information, and belief.

Dated: February 23, 2021 Respectfully submitted,

/s/ Shmuel Vasser

Shmuel Vasser DECHERT LLP 1095 Avenue of the Americas New York, New York 10036 Telephone: (212) 698-3500 Facsimile: (212) 698-3599

shmuel.vasser@dechert.com

Attorneys for Debtors and Debtors in Possession

EXHIBIT A

Description of Legal Services



1095 Avenue of the Americas New York, NY 10036-6797 FED. ID. 23-1425587 www.dechert.com

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003983

Firm Client Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.

Matter Name: Mediation & Settlement, Claims Evaluation, and Operations

Electronic Billing Number: 20210003064

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 552,838.58 |
|-----------------------------------|----------------|
| TOTAL DISBURSEMENTS THIS INVOICE | 251.38 |
| NET TOTAL FEES THIS INVOICE | 552,587.20 |
| Less 20% Discount | (138,146.80) |
| TOTAL FEES THIS INVOICE | 690,734.00 |

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Main Document

Invoice 1010003983 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

| <u>Date</u> | TIMEKEEPER | Hours TA | <u>ISK</u> | <u>ACTIVITY</u> | <u>Amount</u> |
|---------------|--|------------------------------|-------------------------|-----------------------|---------------|
| B110 – Case A | Administration | | | | |
| 12/04/20 | Shmuel Vasser | 0.30 | B110 | A104 | 274.50 |
| | Address payment of litigation service provi | ders (0.3). | | | |
| 12/11/20 | Matthew Stone | 0.30 | B110 | A101 | 60.00 |
| | Arrange telephonic appearances for S. Birn December 15 omnibus hearing. | baum and H | . Colemai | n at | |
| B110 SUBTO | TAL HOURS AND FEES: | 0.60 | | | 334.50 |
| B310 – Claim | s Administration and Objections | | | | |
| 12/08/20 | Shmuel Vasser | 1.00 | B310 | A104 | 915.00 |
| | Review various pleadings regarding claims | filing and rel | ated dea | dline. | |
| 12/10/20 | Shmuel Vasser | 0.70 | B310 | A104 | 640.50 |
| | Review status of claim process/valuation. | | | | |
| 12/17/20 | Shmuel Vasser | 1.00 | B310 | A103 | 915.00 |
| | Review various pleadings for immediate cla | ims paymen | ts. | | |
| B310 SUBTO | TAL HOURS AND FEES: | 2.70 | | | 2,470.50 |
| | | | | | |
| L120 – Analys | sis/Strategy | | | | |
| 12/01/20 | Sheila Birnbaum | 3.60 | L120 | A104 | 4,860.00 |
| | Review materials on McKinsey issues (0.7); insurers and email comments (0.6); review revision for insurer (0.6); review slides and (0.8); review claims valuation estimate and review reports on Purdue (0.4). | confidential engage in he | ity agree earing pre | ment and eparation | |
| 12/01/20 | Sheila Birnbaum | 0.80 | L120 | A108 | 1,080.00 |
| | Attend Purdue weekly lawyers call regardir | ng litigation s | tatus and | d updates. | |
| 12/01/20 | Jenna Newmark | 0.30 | L120 | A103 | 256.50 |
| | Draft and revise email correspondence regards syndrome class claims in West Virginia cases | _ | atal absti | nence | |
| 12/01/20 | Lindsay Zanello | 0.20 | L120 | A107 | 160.00 |
| | Communicate with local counsel regarding claims in West Virginia (.2). | neonatal ab | stinence | syndrome | |
| 12/01/20 | Lindsay Zanello | 0.10 | L120 | A105 | 80.00 |
| | Communicate internally regarding neonata West Virginia (.1). | l abstinence | syndrom | ne claims in | |
| 12/01/20 | Antonella Capobianco-Ranallo | 0.40 | L120 | A102 | 80.00 |
| | Conduct research regarding WV neonatal a | bstinence sy | ndrome | claims. | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 16 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983

Page 3

| <u>Date</u> | TIMEKEEPER | Hours 1 | <u>Task</u> | <u>ACTIVITY</u> | AMOUNT |
|-------------|---|-----------------------|-------------|-----------------|----------|
| 12/02/20 | Sheila Birnbaum | 0.90 | L120 | A106 | 1,215.00 |
| | Telephone conference with Purdue and A. S. (0.4); telephone conference with R. Silbert re | _ | _ | | |
| 12/02/20 | Sheila Birnbaum | 0.50 | L120 | A105 | 675.00 |
| | Telephone conference with Dechert team re | garding c | ase status | (0.5). | |
| 12/02/20 | Sheila Birnbaum | 1.90 | L120 | A104 | 2,565.00 |
| | Review insurance documents for confidential (0.6); review letter to insurers (0.8). | ality (0.5); | review fin | ancial slides | |
| 12/02/20 | Hayden Coleman | 2.90 | L120 | A106 | 2,653.50 |
| | Conference call with client regarding respon correspond with client and retained counsel communicate with client, Dechert and DPW (1.1). | regarding | g same (.7) | ; | |
| 12/02/20 | Hayden Coleman | 0.80 | L120 | A105 | 732.00 |
| | Conference call with Dechert team regarding projects (.5); communicate with Dechert tea abstinence syndrome claims (.3). | | _ | | |
| 12/03/20 | Sheila Birnbaum | 1.50 | L120 | A106 | 2,025.00 |
| | Telephone conference with S. Gilbert, Deche insurance issues (0.8); telephone conference regarding insurance issues (0.3); telephone of Smith, and Purdue regarding insurance issues | with Pur conferenc | due & Ree | d Smith | |
| 12/03/20 | Sheila Birnbaum | 0.70 | L120 | A108 | 945.00 |
| | Telephone conference with third-party payo (0.7). | r lawyers | regarding | plan process | |
| 12/03/20 | Hayden Coleman | 1.50 | L120 | A104 | 1,372.50 |
| | Review and analyze proposed liability languate review and analyze DPW memorandum regatevaluation process (0.8). | • | | , ,, | |
| 12/03/20 | Hayden Coleman | 0.60 | L120 | A106 | 549.00 |
| | Conference with client regarding proposed I contract (0.6). | iability lar | nguage of o | distributor | |
| 12/03/20 | Hayden Coleman | 0.90 | L120 | A107 | 823.50 |
| | Conference call with counsel for Ad Hoc Con party payor claims (0.5); communicate with neonatal abstinence syndrome claimants reg | Dechert to | eam and co | ounsel for | |
| 12/03/20 | Sara Roitman | 1.10 | L120 | A105 | 1,006.50 |
| | Communicate with Dechert team regarding claims valuation (1.1). | plan confi | rmation is: | sues and | |
| 12/03/20 | Erik Snapp | 0.50 | L120 | A105 | 457.50 |
| | Correspondence with internal team regarding Physicians for Responsible Opioid Prescribing | _ | issues rega | arding | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document

Pg 17 of 107

Invoice 1010003983

Page 4

| <u>Date</u> | Тімекеерек | Hours Ta | <u>SK</u> | ACTIVITY | <u>Amount</u> |
|-------------|---|---------------|-------------|-----------------|---------------|
| 12/03/20 | Sarah Magen | 0.40 | L120 | A104 | 342.00 |
| | Review documents regarding claims valuati | on materials | i. | | |
| 12/03/20 | Danielle Gentin Stock | 0.50 | L120 | A105 | 445.00 |
| | Correspond internally and with client regard hearing (0.2); correspond internally regardi | | _ | | |
| 12/03/20 | Paul LaFata | 0.30 | L120 | A104 | 267.00 |
| | Analyze proposed revisions to MDL agenda | | | | |
| 12/03/20 | Paul LaFata | 0.20 | L120 | A104 | 178.00 |
| | Analyze status conference report in Aguirre | (N.M). | | | |
| 12/03/20 | Jonathan Tam | 0.50 | L120 | A107 | 445.00 |
| | Communicate in firm and with co-counsel r | egarding clai | ims analy | rsis (0.5). | |
| 12/04/20 | Sheila Birnbaum | 0.70 | L120 | A104 | 945.00 |
| | Review claims data materials (0.7). | | | | |
| 12/04/20 | Hayden Coleman | 0.90 | L120 | A106 | 823.50 |
| | Emails and conferences with client regarding | g pharmacy | contract | S. | |
| 12/04/20 | Hayden Coleman | 1.00 | L120 | A104 | 915.00 |
| | Review Purdue claims analysis in order to u | pdate Deche | ert team. | | |
| 12/04/20 | Hayden Coleman | 0.50 | L120 | A107 | 457.50 |
| | Attend WebEx with DPW to address legal is calls. | sues in adva | nce of Co | ornerstone | |
| 12/04/20 | Mara Cusker Gonzalez | 1.00 | L120 | A108 | 915.00 |
| | Attend meetings with bankruptcy counsel a public and private claims and valuation ana | _ | counsel | regarding | |
| 12/04/20 | Mara Cusker Gonzalez | 1.40 | L120 | A104 | 1,281.00 |
| | Review updated public and private claims a | nd valuation | analyses | 5. | |
| 12/04/20 | Hope Freiwald | 0.80 | L120 | A104 | 872.00 |
| | Prepare analysis related to plaintiff experts Opioid Prescribing board connections. | with Physici | ans for R | esponsible | |
| 12/04/20 | Sara Roitman | 1.20 | L120 | A104 | 1,098.00 |
| | Analyze valuation analysis for public, privat (1.2). | e, and comm | nercial cla | aimants | |
| 12/04/20 | Sara Roitman | 0.80 | L120 | A103 | 732.00 |
| | Draft summary and analysis of open issues | (0.8). | | | |
| 12/04/20 | Jenna Newmark | 1.00 | L120 | A107 | 855.00 |
| | Participate in videoconference with Davis P claims analysis (1.0). | olk team reg | arding st | atus of | |
| 12/04/20 | Jenna Newmark | 0.40 | L120 | A105 | 342.00 |
| | Participate in telephone call with Dechert to analysis (0.4). | eam regardir | ng status | of claims | |
| 12/04/20 | Danielle Gentin Stock | 0.60 | L120 | A105 | 534.00 |
| | Confer internally regarding claims analysis (| (0.6). | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 18 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 5

| DATE | TIMEKEEPER | Hours Task | ACTIVITY | AMOUNT |
|----------|--|----------------------|-----------------|----------|
| 12/04/20 | Danielle Gentin Stock | 0.40 L12 | 20 A104 | 356.00 |
| | Review claims analysis materials (0.2); review claims analysis (0.2). | w correspondence | e regarding | |
| 12/04/20 | Danielle Gentin Stock | 0.70 L12 | 20 A107 | 623.00 |
| | Confer with co-counsel regarding claims ana | lysis (0.7). | | |
| 12/04/20 | Danielle Gentin Stock | 0.70 L12 | 20 A106 | 623.00 |
| | Communicate with client regarding custome | r query (0.7). | | |
| 12/04/20 | Jonathan Tam | 1.00 L12 | 20 A105 | 890.00 |
| | Communicate internally regarding claims and | alyses (1.0). | | |
| 12/04/20 | Jonathan Tam | 0.70 L12 | 20 A107 | 623.00 |
| | Strategize and confer with co-counsel regard | ding claims analyse | es (0.7). | |
| 12/04/20 | Jonathan Tam | 1.30 L12 | 20 A107 | 1,157.00 |
| | Strategize and confer with co-counsel and ex (1.3). | xperts regarding cl | laims analyses | |
| 12/07/20 | Sheila Birnbaum | 1.20 L12 | 20 A104 | 1,620.00 |
| | Review terms sheet of Multi-state Governme materials (0.8); review report to monitor (0.4) | | up and related | |
| 12/07/20 | Danielle Gentin Stock | 0.20 L12 | 20 A105 | 178.00 |
| | Correspond internally regarding various Purc | due workstreams. | | |
| 12/07/20 | Danielle Gentin Stock | 0.20 L12 | 20 A106 | 178.00 |
| | Correspond with client regarding Monitor re related material (0.2). | port follow up and | d review | |
| 12/08/20 | Sheila Birnbaum | 0.80 L12 | 20 A107 | 1,080.00 |
| | Telephone conference with Purdue lawyers | regarding status o | of litigation. | |
| 12/08/20 | Sheila Birnbaum | 2.30 L12 | 20 A104 | 3,105.00 |
| | Review materials regarding McKinsey issues state Governmental Entities Group (0.7); rev | • • • | | |
| 12/08/20 | Hayden Coleman | 1.50 L12 | 20 A104 | 1,372.50 |
| | Review and respond to emails and memos fr claims (1.1). | om DPW regardin | ng Canadian | |
| 12/08/20 | Hayden Coleman | 0.80 L12 | 20 A106 | 732.00 |
| | Plan for and participate in weekly principals retained counsel (0.8). | call with client and | d other | |
| 12/08/20 | Sara Roitman | 0.80 L12 | 20 A105 | 732.00 |
| | Communicate with Dechert team regarding of public, private, and commercial claimants. | claim and liquidati | ion analysis of | |
| 12/08/20 | Sarah Magen | 1.90 L12 | 20 A102 | 1,624.50 |
| | Research and summarize arguments regarding | ng claims precede | nt. | |
| 12/08/20 | Sarah Magen | 0.50 L12 | 20 A105 | 427.50 |
| | Communicate internally regarding pre-2007 | claims research. | | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/23/21 Entered 02/23/21 17:59:58

Main Document Pg 19 of 107

Invoice 1010003983 Page 6

| DATE | TIMEKEEPER | Hours Tas | к Астіуіту | AMOUNT |
|----------|--|----------------|---------------------|----------|
| 12/08/20 | Danielle Gentin Stock | 1.70 | L120 A106 | 1,513.00 |
| | Confer with client regarding follow up to M participate on client update call (0.9). | lonitor recom | mendations (0.8); | · |
| 12/09/20 | Sheila Birnbaum | 0.30 | L120 A104 | 405.00 |
| | Review materials for NAACP (0.3). | | | |
| 12/09/20 | Hayden Coleman | 0.50 | L120 A104 | 457.50 |
| | Review and comment on memorandum re | garding McKir | sey issues (.5). | |
| 12/09/20 | Hayden Coleman | 0.60 | L120 A107 | 549.00 |
| | Communicate with DPW and Dechert regar | rding Canadia | n claims (.6). | |
| 12/09/20 | Mara Cusker Gonzalez | 0.80 | L120 A104 | 732.00 |
| | Review analysis regarding Canadian public regarding same. | claims and st | ategy for valuation | |
| 12/09/20 | Sarah Magen | 3.10 | L120 A104 | 2,650.50 |
| | Review Canadian counsel memorandum ar valuation (1.7); analyze findings regarding s | | regarding claims | |
| 12/09/20 | Jenna Newmark | 0.50 | L120 A103 | 427.50 |
| | Draft summary of call with Cornerstone an claimant groups (0.5). | d Davis Polk r | egarding additional | |
| 12/09/20 | Danielle Gentin Stock | 0.20 | L120 A106 | 178.00 |
| | Correspond with client regarding Monitor (| (0.2). | | |
| 12/09/20 | Jonathan Tam | 1.00 | L120 A107 | 890.00 |
| | Confer with co-counsel regarding claims an | nalysis (1.0). | | |
| 12/10/20 | Sheila Birnbaum | 3.10 | L120 A109 | 4,185.00 |
| | Attend board meeting. | | | |
| 12/10/20 | Sheila Birnbaum | 1.60 | L120 A104 | 2,160.00 |
| | Review material for board meeting (0.6); red documents and emails (1.0). | eview drafts o | f insurance | |
| 12/10/20 | Mara Cusker Gonzalez | 0.50 | L120 A104 | 457.50 |
| | Review analysis by Canadian counsel of Car | nadian claims | valuation. | |
| 12/10/20 | Sara Roitman | 2.00 | L120 A104 | 1,830.00 |
| | Analyze and review updated valuation estil payors, neonatal abstinence syndrome clai | | | |
| 12/10/20 | Shmuel Vasser | 0.50 | L120 A104 | 457.50 |
| | Review status of various discovery disputes | s. | | |
| 12/10/20 | Sarah Magen | 1.10 | L120 A101 | 940.50 |
| | Prepare for call with Canada counsel regard memorandum and findings. | ding claims ev | aluation | |
| 12/10/20 | Danielle Gentin Stock | 0.10 | L120 A106 | 89.00 |
| | Correspond with client regarding follow up | to Monitor re | eport. | |
| 12/10/20 | Danielle Gentin Stock | 0.40 | L120 A105 | 356.00 |
| | Confer internally regarding workflows and | requested do | cuments (0.4). | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 20 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 7

| DATE | <u>TIMEKEEPER</u> | Hours Tas | <u>sk</u> | ACTIVITY | AMOUNT |
|----------------------|---|---|---|---------------|-----------------|
| 12/11/20 | Sheila Birnbaum | 3.20 | L120 | A104 | 4,320.00 |
| | Review case update reports (0.4); review tra (0.5); review and revise statement to Congr structure (0.5); review materials on manage filed documents (0.7). | ess (0.5); rev | view ema | nils on plan | |
| 12/11/20 | Hayden Coleman | 0.40 | L120 | A105 | 366.00 |
| | Communicate with Dechert team regarding | valuation of | Canadia | n claims. | |
| 12/11/20 | Hayden Coleman | 0.60 | L120 | A106 | 549.00 |
| | Communicate with client, Dechert, and DPV implicated by media motion to unseal. | V regarding r | review o | f documents | |
| 12/11/20 | Hayden Coleman | 1.00 | L120 | A107 | 915.00 |
| | Participate in WebEx regarding claims analy | sis with DPW | V and De | chert. | |
| 12/11/20 | Mara Cusker Gonzalez | 0.80 | L120 | A104 | 732.00 |
| | Review legal analyses in connection with cla | ims analysis | and val | uation (0.8). | |
| 12/11/20 | Mara Cusker Gonzalez | 1.20 | L120 | A107 | 1,098.00 |
| | Attend meetings with bankruptcy counsel a claims analysis and valuation regarding prep (1.2). | _ | | | |
| 12/11/20 | Sara Roitman | 2.80 | L120 | A104 | 2,562.00 |
| | Review valuation analysis for commercial, p | rivate, and p | ublic cla | imants (2.8). | |
| 12/11/20 | Sarah Magen | 2.30 | L120 | A107 | 1,966.50 |
| | Call with DPW and Canadian counsel regard for call (.5); draft and revise call notes (.8). | ing case stra | itegy (1.0 |)); prepare | |
| 12/11/20 | Jenna Newmark | 2.10 | L120 | A108 | 1,795.50 |
| | Participate in videoconference with Canadia analysis (1.0); draft email correspondence r with Davis Polk team (0.2); participate in vic Davis Polk teams regarding claims analysis (| egarding age leoconferend | enda for | meeting | |
| 12/11/20 | Danielle Gentin Stock | 2.00 | L120 | A107 | 1,780.00 |
| | Confer with co-counsel regarding claims and co-counsel regarding next steps in claims ar | | s (0.7); c | onfer with | |
| 12/11/20 | Jonathan Tam | 1.00 | L120 | A107 | 890.00 |
| | Confer with co-counsel regarding claims and | alyses (1.0). | | | |
| 12/14/20 | Sheila Birnbaum | 0.40 | L120 | A105 | 540.00 |
| | | | | _ | |
| | Telephone conference with Dechert team re | egarding case | e projec | is. | |
| 12/14/20 | Telephone conference with Dechert team re Hayden Coleman | egarding case 0.50 | | A105 | 457.50 |
| 12/14/20 | · | 0.50 | L120 | A105 | 457.50 |
| 12/14/20 12/14/20 | Hayden Coleman | 0.50 | L120 am (0.5) | A105 | 457.50 85.50 |
| | Hayden Coleman Attend update and strategy conference with | 0.50 n Dechert tea 0.10 | L120 am (0.5) L120 | A105 | |
| | Hayden Coleman Attend update and strategy conference with Jenna Newmark | 0.50 n Dechert tea 0.10 | L120 am (0.5) L120 n (0.1) | A105 | |
| 12/14/20 | Hayden Coleman Attend update and strategy conference with Jenna Newmark Review email correspondence regarding cla | 0.50 n Dechert tea 0.10 ims valuation 0.70 | L120 am (0.5) L120 n (0.1) L120 | A104 | 85.50 |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 21 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 8

| D ATE | TIMEKEEPER | Hours Tas | <u>K</u> | ACTIVITY | <u>Amount</u> |
|--------------|---|-----------------|-----------|---------------|---------------|
| 12/15/20 | Sheila Birnbaum | 1.80 | L120 | A104 | 2,430.00 |
| | Review insurance materials for insurer (0.8); meeting for minutes (0.4); review case upda | | | rding setting | |
| 12/15/20 | Hayden Coleman | 1.00 | L120 | A106 | 915.00 |
| | Participate in WebEx principals meeting with (0.6); communicate with client, DPW, and Do (0.4). | | | | |
| 12/15/20 | Sarah Magen | 3.40 | L120 | A102 | 2,907.00 |
| | Research regarding claims allocation models regarding claims valuations (1.3). | s (2.1); reviev | v mater | ials | |
| 12/15/20 | Lindsey Cohan | 1.00 | L120 | A104 | 890.00 |
| | Compile information in response to request negotiating class. | relating to p | roposed | d MDL | |
| 12/15/20 | Danielle Gentin Stock | 0.30 | L120 | A106 | 267.00 |
| | Correspond with client regarding Monitor m | aterials and | next ste | eps (0.3). | |
| 12/15/20 | Danielle Gentin Stock | 0.60 | L120 | A106 | 534.00 |
| | Participate on client update call with co-cou | nsel. | | | |
| 12/16/20 | Sheila Birnbaum | 1.20 | L120 | A104 | 1,620.00 |
| | Review materials on neonatal abstinence symmeterials on new monitor appointment (0.7 | | ns (0.5) | ; review | |
| 12/16/20 | Mara Cusker Gonzalez | 0.90 | L120 | A104 | 823.50 |
| | Review updated valuation analyses from litig | gation team. | | | |
| 12/16/20 | Mara Cusker Gonzalez | 0.60 | L120 | A107 | 549.00 |
| | Attend strategy call with litigation counsel reanalyses. | egarding upd | lated va | lluation | |
| 12/16/20 | Sara Roitman | 2.50 | L120 | A104 | 2,287.50 |
| | Review and analyze public claimants' term s regarding same (0.6); analyze issues regarding (0.6). | | | - | |
| 12/16/20 | Sarah Magen | 2.20 | L120 | A102 | 1,881.00 |
| | Research regarding claim allocation models | (2.2). | | | |
| 12/16/20 | Sarah Magen | 1.70 | L120 | A105 | 1,453.50 |
| | Communicate internally regarding claim allo Coleman and S. Roitman regarding claims va | | | | |
| 12/16/20 | Jenna Newmark | 1.00 | L120 | A105 | 855.00 |
| | Videoconference with Dechert team regardi | ng claims and | alysis (1 | 0) | |
| 12/16/20 | Danielle Gentin Stock | 2.60 | L120 | A102 | 2,314.00 |
| | Conduct research regarding potential Monit regarding the same (0.9). | or (1.7); prep | oare sur | nmary | |
| 12/17/20 | Sheila Birnbaum | 0.70 | L120 | A104 | 945.00 |
| | Review reports on Congressional hearing (0. | 7). | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 22 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983

Page 9

| DATE | TIMEKEEPER | Hours 1 | T ASK | ACTIVITY | Amount |
|----------|--|--------------|--------------|----------------|----------|
| 12/17/20 | Sheila Birnbaum | 0.70 | | A105 | 945.00 |
| | Team call regarding Congressional meeting Dechert team regarding projects (0.4). | (0.3); telep | ohone con | ference with | |
| 12/17/20 | Sara Roitman | 1.10 | L120 | A105 | 1,006.50 |
| | Communicate with Dechert team regarding party payor claims. | valuation | of hospita | l and Third | |
| 12/17/20 | Sarah Magen | 3.30 | L120 | A104 | 2,821.50 |
| | Analyze third party payor and hospital claim | ns. | | | |
| 12/17/20 | Sarah Magen | 0.60 | L120 | A105 | 513.00 |
| | Communicate internally regarding third par | ty payor a | nd hospita | l claims. | |
| 12/17/20 | Jenna Newmark | 1.00 | L120 | A105 | 855.00 |
| | Prepare email to team analyzing proposed a | adjustmen | ts to public | c claims (1.0) | |
| 12/17/20 | Jonathan Tam | 0.70 | L120 | A104 | 623.00 |
| | Review and analyze research in preparation regarding claims analyses (0.7). | for meeti | ng with ex | perts | |
| 12/17/20 | Antonella Capobianco-Ranallo | 1.00 | L120 | A102 | 200.00 |
| | Gather information as to third party payors | and hospi | tals lawsui | ts. | |
| 12/18/20 | Sheila Birnbaum | 2.30 | L120 | A104 | 3,105.00 |
| | Review materials from House Oversight (0.8 Committee regarding Common Interest Privnew monitor (0.5). | - | | | |
| 12/18/20 | Hayden Coleman | 0.70 | L120 | A105 | 640.50 |
| | Communicate with Dechert team regarding regarding third party payor and hospital cla | | limitation | s issues | |
| 12/18/20 | Hayden Coleman | 1.00 | L120 | A107 | 915.00 |
| | Participate in WebEx with Cornerstone, DP\ claims assessment. | W, and Ded | chert team | regarding | |
| 12/18/20 | Mara Cusker Gonzalez | 1.80 | L120 | A108 | 1,647.00 |
| | Attend meeting with outside consultants, be counsel regarding ongoing claims analysis a confer with litigation and bankruptcy couns analysis and valuation strategy (0.8). | nd valuation | on strategy | / (1.0); | |
| 12/18/20 | Sarah Magen | 2.80 | L120 | A104 | 2,394.00 |
| | Analyze third party payor and hospital claim | ıs. | | | |
| 12/18/20 | Jenna Newmark | 0.70 | L120 | A107 | 598.50 |
| | Participate in videoconference with Davis P valuation (0.7). | olk team r | egarding c | laims | |
| 12/18/20 | Danielle Gentin Stock | 0.20 | L120 | A106 | 178.00 |
| | Correspond with client regarding Monitor is | ssues. | | | |
| 12/18/20 | Danielle Gentin Stock | 0.30 | L120 | A104 | 267.00 |
| | Review correspondence and materials relat (0.3). | ed to post | -emergend | e structure | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 23 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 10

| <u>Date</u> | TIMEKEEPER | Hours Ta | <u>SK</u> | ACTIVITY | <u>Amount</u> |
|-------------|---|---|------------|--------------|---------------|
| 12/18/20 | Danielle Gentin Stock | 1.00 | L120 | A107 | 890.00 |
| | Participate on call with co-counsel concernir | ng claims an | alysis. | | |
| 12/18/20 | Paul LaFata | 0.70 | L120 | A107 | 623.00 |
| | Confer with co-defense counsel regarding pr disclosures (0.3); analyze proposed revisions | - | isions to | regulatory | |
| 12/18/20 | Jonathan Tam | 0.60 | L120 | A107 | 534.00 |
| | Confer with co-counsel regarding claims ana | lyses (0.6). | | | |
| 12/18/20 | Jonathan Tam | 0.40 | L120 | A104 | 356.00 |
| | Review and analyze research in preparation (0.4). | for confere | nce with | co-counsel | |
| 12/18/20 | Antonella Capobianco-Ranallo | 0.20 | L120 | A104 | 40.00 |
| | Review FDA website regarding OxyContin lab | oel. | | | |
| 12/19/20 | Sheila Birnbaum | 0.70 | L120 | A104 | 945.00 |
| | Review bankruptcy term sheet. | | | | |
| 12/20/20 | Sheila Birnbaum | 0.40 | L120 | A104 | 540.00 |
| | Review insurance confidentiality order (0.4). | | | | |
| 12/21/20 | Sheila Birnbaum | 0.70 | L120 | A107 | 945.00 |
| | Telephone conference with Ad Hoc Committ (0.4); review emails regarding same (0.3). | ee regardin | ig insurai | nce issues | |
| 12/21/20 | Sheila Birnbaum | 0.50 | L120 | A104 | 675.00 |
| | Review case update reports (0.5). | | | | |
| 12/21/20 | Hayden Coleman | 0.60 | L120 | A106 | 549.00 |
| | Respond to client inquiries regarding Rhodes with client and DPW team regarding same (C | = | (0.3); co | mmunicate | |
| 12/21/20 | Hayden Coleman | 0.70 | L120 | A105 | 640.50 |
| | Participate in conference call with Dechert to and hospital claims. | eam regardi | ing third- | -party payor | |
| 12/21/20 | Hayden Coleman | 0.50 | L120 | A108 | 457.50 |
| | Participate in meet-and-confer with neonata committee. | al abstinence | e syndro | me | |
| 12/21/20 | Mara Cusker Gonzalez | 0.60 | L120 | A103 | 549.00 |
| | Prepare analysis regarding approach to state with commercial claims valuation. | ute of limita | tions cor | nnection | |
| 12/21/20 | Sara Roitman | 1.30 | L120 | A105 | 1,189.50 |
| | Communicate with Dechert team regarding party payor, neonatal abstinence syndrome, | | | | |
| 12/21/20 | Sarah Magen | 0.60 | L120 | A105 | 513.00 |
| | Call regarding claims valuation analysis with | S. Roitman | and J. Ne | ewmark (.6). | |
| 12/21/20 | Danielle Gentin Stock | 1.10 | L120 | A106 | 979.00 |
| | Prepare for (0.5) and participate on client ca with Monitor recommendations. | ll (0.6) to di | scuss co | mpliance | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 24 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 11

| DATE | Тімекеерек | Hours Ta | <u>ACTIVITY</u> | AMOUNT |
|----------|---|---------------|-----------------------|----------|
| 12/21/20 | Danielle Gentin Stock | 0.20 | L120 A104 | 178.00 |
| | Review analysis of newly filed Adversary Pr | oceeding. | | |
| 12/21/20 | Paul LaFata | 0.50 | L120 A107 | 445.00 |
| | Confer with client and co-defense counsel r submission. | egarding rev | isions to regulatory | |
| 12/22/20 | Sheila Birnbaum | 1.00 | L120 A106 | 1,350.00 |
| | Telephone conference with Purdue legal te (1.0). | am regarding | litigation update | |
| 12/22/20 | Sheila Birnbaum | 2.00 | L120 A104 | 2,700.00 |
| | Review and respond to insurance emails (0. emails (0.8); review term sheet change (0.8 | - | ructure drafts and | |
| 12/22/20 | Sheila Birnbaum | 0.90 | L120 A109 | 1,215.00 |
| | Attend meeting of Special Committee of Bo | ard. | | |
| 12/22/20 | Hayden Coleman | 1.20 | L120 A107 | 1,098.00 |
| | Plan for and participate in weekly client cal | with retaine | d counsel. | |
| 12/22/20 | Hayden Coleman | 1.30 | L120 A104 | 1,189.50 |
| | Review and comment on presentation to st company (1.1); review email to Court regar syndrome Committee (0.2). | | | |
| 12/22/20 | Hayden Coleman | 1.00 | L120 A107 | 915.00 |
| | Participate in WebEx with Cornerstone, DP analysis. | W and Deche | rt regarding claims | |
| 12/22/20 | Mara Cusker Gonzalez | 1.40 | L120 A108 | 1,281.00 |
| | Attend meeting with outside consultants, be counsel regarding public and private claims confer with litigation counsel regarding stra | analysis and | valuation (1.0); | |
| 12/22/20 | Sara Roitman | 1.30 | L120 A104 | 1,189.50 |
| | Analyze issues regarding Negotiation Class municipality valuation regarding same. | allocation mo | odel and impact on | |
| 12/22/20 | Sara Roitman | 0.90 | L120 A105 | 823.50 |
| | Communicate with Purdue team regarding valuation and strategy, and plan confirmati | • | ivate claimant | |
| 12/22/20 | Danielle Gentin Stock | 1.90 | L120 A107 | 1,691.00 |
| | Participate on call with co-counsel concern | ng claims an | alysis. | |
| 12/22/20 | Danielle Gentin Stock | 1.10 | L120 A106 | 979.00 |
| | Participate on client update call. | | | |
| 12/22/20 | Danielle Gentin Stock | 0.90 | L120 A105 | 801.00 |
| | Confer (.5) and correspond internally (.4) re | garding third | l party payor claims. | |
| 12/22/20 | Danielle Gentin Stock | 1.40 | L120 A104 | 1,246.00 |
| | Review and analyze materials and research claims. | concerning t | hird party payor | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 25 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983

Page 12

| DATE | TIMEKEEPER | Hours Tas | <u>sk</u> | ACTIVITY | AMOUNT |
|----------|---|---------------|------------|---------------|----------|
| 12/22/20 | Danielle Gentin Stock | 0.30 | L120 | A104 | 267.00 |
| | Review and analyze and annotate Voluntary | Injunction. | | | |
| 12/22/20 | Paul LaFata | 0.20 | L120 | A104 | 178.00 |
| | Analyze revisions to regulatory communicat | ion. | | | |
| 12/23/20 | Sheila Birnbaum | 1.90 | L120 | A104 | 2,565.00 |
| | Review case update reports (0.5); review an insurance (0.6); review emails regarding pos review materials on tribes allocation (0.4). | • | | • | |
| 12/23/20 | Hayden Coleman | 1.20 | L120 | A104 | 1,098.00 |
| | Review presentation given to states regarding options. | ng post-eme | rgence s | tructure | |
| 12/23/20 | Sara Roitman | 0.80 | L120 | A104 | 732.00 |
| | Analyze issues regarding statute of limitation hospital claims (0.3); review case law regard | | | or and | |
| 12/23/20 | Danielle Gentin Stock | 0.20 | L120 | A105 | 178.00 |
| | Correspond internally regarding claims analy | ysis. | | | |
| 12/23/20 | Danielle Gentin Stock | 0.20 | L120 | A104 | 178.00 |
| | Review correspondence regarding post-eme | ergence struc | cture and | d SOL issues. | |
| 12/23/20 | Danielle Gentin Stock | 1.40 | L120 | A104 | 1,246.00 |
| | Analyze Monitor issues. | | | | |
| 12/23/20 | Danielle Gentin Stock | 0.60 | L120 | A105 | 534.00 |
| | Correspond internally regarding Monitor iss | ues. | | | |
| 12/28/20 | Sheila Birnbaum | 1.10 | L120 | A104 | 1,485.00 |
| | Review emails regarding insurance (0.4); rev (0.7). | view materia | ls on pla | n status | |
| 12/28/20 | Danielle Gentin Stock | 1.10 | L120 | A104 | 979.00 |
| | Prepare updates Monitor presentation and | overview de | ck (1.1). | | |
| 12/29/20 | Sheila Birnbaum | 0.50 | L120 | A104 | 675.00 |
| | Review emails and agreements regarding in | surance (0.5 |). | | |
| 12/29/20 | Paul LaFata | 0.30 | L120 | A104 | 267.00 |
| | Analyze proposed revisions to regulatory su | bmission (0. | 3). | | |
| 12/29/20 | Paul LaFata | 0.20 | L120 | A106 | 178.00 |
| | Confer with client regarding proposed revisi (0.2). | ons to regula | atory sul | omission | |
| 12/30/20 | Sheila Birnbaum | 2.40 | L120 | A104 | 3,240.00 |
| | Review newly filed pleadings (0.5); review e (0.4); review term sheet drafts (0.7); work o | _ | _ | | |
| 12/30/20 | Sheila Birnbaum | 0.80 | L120 | A105 | 1,080.00 |
| | Telephone conference with Dechert team re | egarding case | e status a | and updates. | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 26 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405

12/03/20

Paul LaFata

Invoice 1010003983 Page 13

VALUES ON THIS INVOICE ARE BILLED IN USD

| DATE | TIMEKEEPER | Hours Tas | <u>sk</u> | <u>ACTIVITY</u> | <u>Amount</u> |
|-------------|---|----------------|-----------|-----------------|---------------|
| 12/30/20 | Hayden Coleman | 1.00 | L120 | A107 | 915.00 |
| | Participate in WebEx with Cornerstone, DP claims estimation. | W, and Deche | ert team | s regarding | |
| 12/30/20 | Hayden Coleman | 0.60 | L120 | A107 | 549.00 |
| | Conference call with DPW regarding legal is estimation. | ssues underly | ing clain | ns | |
| 12/30/20 | Mara Cusker Gonzalez | 0.60 | L120 | A107 | 549.00 |
| | Attend video meeting with bankruptcy cou analysis and valuation. | nsel regardin | g ongoir | ng claims | |
| 12/30/20 | Danielle Gentin Stock | 0.50 | L120 | A107 | 445.00 |
| | Confer with co-counsel regarding claims an | alysis. | | | |
| 12/30/20 | Danielle Gentin Stock | 0.70 | L120 | A108 | 623.00 |
| | Confer with experts and co-counsel regardi | ng claims and | alysis. | | |
| 12/30/20 | Danielle Gentin Stock | 0.90 | L120 | A105 | 801.00 |
| | Prepare for (0.2) and confer internally (0.7) updates. | regarding m | onitor a | nd other | |
| 12/30/20 | Danielle Gentin Stock | 0.20 | L120 | A104 | 178.00 |
| | Review summary of newly filed pleadings. | | | | |
| 12/30/20 | Paul LaFata | 0.30 | L120 | A106 | 267.00 |
| | Analyze proposed revisions to regulatory su | ubmission (0. | 3). | | |
| 12/30/20 | Paul LaFata | 0.30 | L120 | A106 | 267.00 |
| | Confer with client regarding revisions to re | gulatory subn | mission (| 0.3). | |
| 12/31/20 | Sarah Magen | 1.40 | L120 | A102 | 1,197.00 |
| | Research regarding third party payor claims | s objections. | | | |
| L120 SUBTO | TAL HOURS AND FEES: | 170.50 | | | 171,163.00 |
| L130 – Expe | rts/Consultants | | | | |
| 12/02/20 | Sara Roitman | 1.60 | L130 | A104 | 1,464.00 |
| | Review and analyze consultant's proposed | valuation est | imation | (1.6). | |
| 12/02/20 | Sara Roitman | 1.40 | L130 | A103 | 1,281.00 |
| | Draft summary regarding consultant's prop | osed valuation | on estim | ation (1.4). | |
| 12/03/20 | Sara Roitman | 2.50 | L130 | A104 | 2,287.50 |
| | Analyze consultants' liquidation and valuat claimants, private claimants and commercial | | es for pu | blic | |
| 12/03/20 | Jenna Newmark | 1.70 | L130 | A103 | 1,453.50 |
| | Review and analyze Cornerstone analysis o neonatal abstinence syndrome claims (1.2) | | ; prepar | e analysis of | |

0.50

Confer with expert team regarding expert strategy and projects.

L130 A108

445.00

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 27 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 14

| DATE | TIMEKEEPER | Hours Task | · | ACTIVITY | AMOUNT |
|----------|---|-----------------|---------|-----------------|----------|
| 12/04/20 | Sara Roitman | 2.50 | L130 | A108 | 2,287.50 |
| | Communicate with consultants and bankrup valuation and analysis. | tcy counsel re | egardin | ng claims | |
| 12/04/20 | Sara Roitman | 1.40 | L130 | A105 | 1,281.00 |
| | Confer with Dechert team regarding consult liquidation analysis for hospital, third party, | | | | |
| 12/04/20 | Danielle Gentin Stock | 1.30 | L130 | A108 | 1,157.00 |
| | Participate on expert call regarding claims ar | nalysis (1.3). | | | |
| 12/09/20 | Hayden Coleman | 1.00 | L130 | A108 | 915.00 |
| | Conference call with Cornerstone regarding | claims estima | tion (1 | .0). | |
| 12/09/20 | Jenna Newmark | 1.30 | L130 | A107 | 1,111.50 |
| | Participate in call with Cornerstone and Davi claimant groups (1.3). | is Polk regardi | ing add | ditional | |
| 12/09/20 | Danielle Gentin Stock | 0.50 | L130 | A108 | 445.00 |
| | Confer with experts regarding claims analysi | s. | | | |
| 12/10/20 | Jenna Newmark | 0.80 | L130 | A104 | 684.00 |
| | Review and analyze email correspondence for additional claimant groups (0.8) | rom Cornersto | one reg | garding | |
| 12/11/20 | Sheila Birnbaum | 0.50 | L130 | A104 | 675.00 |
| | Review material for Purdue experts (0.5). | | | | |
| 12/11/20 | Sara Roitman | 0.70 | L130 | A107 | 640.50 |
| | Communicate with bankruptcy counsel and analysis for commercial, private, and public | | egardin | ng valuation | |
| 12/11/20 | Sara Roitman | 2.50 | L130 | A104 | 2,287.50 |
| | Analyze consultants' valuation of hospital, the abstinence syndrome, and personal injury cl | | or, nec | onatal | |
| 12/11/20 | Jonathan Tam | 1.20 | L130 | A108 | 1,068.00 |
| | Confer with experts regarding claims analyse | es (1.2). | | | |
| 12/13/20 | Jenna Newmark | 0.30 | L130 | A104 | 256.50 |
| | Review and analyze correspondence from Covaluation (0.3). | ornerstone re | gardinį | g claims | |
| 12/15/20 | Sara Roitman | 0.50 | L130 | A107 | 457.50 |
| | Confer with co-Defendant regarding expert s | strategy issue | S. | | |
| 12/15/20 | Sara Roitman | 2.00 | L130 | A104 | 1,830.00 |
| | Review and revise consultants' summary reg sheet and issues regarding municipal claims | | claima | ant term | |
| 12/15/20 | Jenna Newmark | 0.40 | L130 | A104 | 342.00 |
| | Review and analyze summary of municipality Cornerstone (0.4). | y settlement t | erm sh | neet from | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 28 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 15

| <u>Date</u> | Тімекеерек | Hours Ta | <u>SK</u> | ACTIVITY | AMOUNT |
|-------------|---|--------------------------|------------|-----------------|----------|
| 12/16/20 | Hayden Coleman | 0.50 | L130 | A105 | 457.50 |
| | Conference call with Dechert team regarding questions regarding claims estimation (.5). | g respondinį | g to Corr | nerstone | |
| 12/16/20 | Sara Roitman | 1.40 | L130 | A104 | 1,281.00 |
| | Analyze consultants' analysis of states and n recommendations regarding same (0.6). | nunicipality | damages | s (0.8); draft | |
| 12/16/20 | Sara Roitman | 0.70 | L130 | A104 | 640.50 |
| | Review consultants' valuations regarding pu | blic and mu | nicipal c | laims (0.7). | |
| 12/16/20 | Sara Roitman | 0.90 | L130 | A105 | 823.50 |
| | Communicate with Dechert team regarding public and municipal claims (0.9). | consultants ^a | ' valuatio | ons regarding | |
| 12/17/20 | Sara Roitman | 0.50 | L130 | A107 | 457.50 |
| | Communicate with co-counsel regarding sus issue for co-Defendants. | picious orde | er monit | oring expert | |
| 12/17/20 | Sara Roitman | 1.30 | L130 | A103 | 1,189.50 |
| | Review and revise draft summary regarding public claimant valuation adjustments. | expert reco | mmenda | ations for | |
| 12/18/20 | Sara Roitman | 2.00 | L130 | A104 | 1,830.00 |
| | Analyze issues from consultants regarding cl private claimants. | aim valuatio | on for pu | blic and | |
| 12/18/20 | Jenna Newmark | 2.70 | L130 | A108 | 2,308.50 |
| | Prepare for (1.5) and participate in videocon Cornerstone teams regarding claims analysis | | h Davis f | Polk and | |
| 12/18/20 | Jonathan Tam | 1.00 | L130 | A108 | 890.00 |
| | Confer with experts and co-counsel regarding | ng claims and | alyses (1 | .0). | |
| 12/21/20 | Sara Roitman | 1.50 | L130 | A104 | 1,372.50 |
| | Analyze issues from experts regarding valuate abstinence syndrome claims. | tion of state | e and ned | onatal | |
| 12/21/20 | Jenna Newmark | 0.50 | L130 | A105 | 427.50 |
| | Participate in telephone call with S. Roitman Magen regarding claims analysis calls with C | | | z, and S. | |
| 12/22/20 | Sara Roitman | 1.20 | L130 | A108 | 1,098.00 |
| | Confer with consultants regarding valuation claims and strategy for state and municipalit | - | nd private | e claimant | |
| 12/22/20 | Jenna Newmark | 1.60 | L130 | A107 | 1,368.00 |
| | Prepare for call with Cornerstone regarding in call with Davis Polk team and Cornerstone | - | | - | |
| 12/22/20 | Jonathan Tam | 1.20 | L130 | A108 | 1,068.00 |
| | Confer with experts regarding claims analyse | es (1.2). | | | |
| 12/23/20 | Sheila Birnbaum | 0.50 | L130 | A104 | 675.00 |
| | Review expert analysis on state and neonata (0.5). | al abstinence | e syndro | me claims | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/23/21 Entered 02/23/21 17:59:58

Main Document Pg 29 of 107

Invoice 1010003983 Page 16

| DATE | TIMEKEEPER | Hours Task | <u>ACTIVITY</u> | Amount | | | |
|---------------|--|----------------|----------------------|-----------|--|--|--|
| 12/23/20 | Jenna Newmark | 0.20 | L130 A104 | 171.00 | | | |
| | Review correspondence from Cornerstone r | egarding clair | ns analysis (0.2). | | | | |
| 12/28/20 | Hayden Coleman | 1.10 | L130 A105 | 1,006.50 | | | |
| | Emails and conference calls with Dechert te projects. | am regarding | Cornerstone | | | | |
| 12/30/20 | Jenna Newmark | 1.10 | L130 A107 | 940.50 | | | |
| | Participate in telephone call with Davis Polk team to prepare for call with Cornerstone regarding claims analysis (0.5); participate in telephone call with Davis Polk and Cornerstone team regarding claims analysis (0.6). | | | | | | |
| 12/30/20 | Jonathan Tam | 1.50 | L130 A108 | 1,335.00 | | | |
| | Confer with co-counsel and experts regarding | ng claims anal | yses (1.5). | | | | |
| L130 SUBTOT | AL HOURS AND FEES: | 46.00 | | 41,709.00 | | | |
| | | | | | | | |
| L150 – Budge | ting | | | | | | |
| 12/02/20 | Paul LaFata | 0.20 | L150 A107 | 178.00 | | | |
| | Confer with co-counsel regarding response vendor. | to budget inq | uiry for discovery | | | | |
| L150 SUBTOT | AL HOURS AND FEES: | 0.20 | | 178.00 | | | |
| | | | | | | | |
| L160 – Settle | ment/Non-Binding ADR | | | | | | |
| 12/01/20 | Sheila Birnbaum | 1.30 | L160 A108 | 1,755.00 | | | |
| | Telephone conference with representative of settlement issues (0.5); telephone conferent of consenting states regarding settlement is | ce with anoth | | | | | |
| 12/01/20 | Sheila Birnbaum | 1.80 | L160 A106 | 2,430.00 | | | |
| | Telephone conference with T. Baker, Davis I settlement issues (1.0); telephone conferen regarding settlement issues (0.8). | | | | | | |
| 12/01/20 | Sheila Birnbaum | 0.40 | L160 A104 | 540.00 | | | |
| | Review email regarding public health initiati | ve presentati | on (0.4). | | | | |
| 12/01/20 | Sara Roitman | 0.70 | L160 A104 | 640.50 | | | |
| | Analyze issues regarding potential West Virg syndrome claimants' settlement. | ginia neonatal | abstinence | | | | |
| 12/01/20 | Sara Roitman | 1.50 | L160 A103 | 1,372.50 | | | |
| | Review and revise proposed opening position settlement negotiations. | on statement t | to AIG for insurance | | | | |
| 12/01/20 | Sara Roitman | 2.10 | L160 A105 | 1,921.50 | | | |
| | Communicate with Dechert team regarding (.8), Sackler mediations (.8), and Congressio | | | | | | |
| 12/01/20 | Danielle Gentin Stock | 0.70 | L160 A107 | 623.00 | | | |
| | Participate on client update call with co-cou | nsel regarding | g settlement (0.7). | | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 30 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 17

| DATE | TIMEKEEPER | Hours Task | <u>K</u> | <u>ACTIVITY</u> | AMOUNT |
|----------|---|----------------|----------|-----------------|----------|
| 12/02/20 | Sheila Birnbaum | 1.50 | L160 | A108 | 2,025.00 |
| | Telephone conference with mediators regar telephone conference with mediator regard | _ | - | • | |
| 12/02/20 | Sheila Birnbaum | 0.50 | L160 | A107 | 675.00 |
| | Telephone conference with Purdue and Davissues (0.5). | is Polk regard | ding set | tlement | |
| 12/02/20 | Sara Roitman | 0.50 | L160 | A106 | 457.50 |
| | Confer with client and insurance counsel reg negotiations. | garding insura | ance se | ttlement | |
| 12/02/20 | Sara Roitman | 0.70 | L160 | A104 | 640.50 |
| | Review implications for settlement regardin Allergan document issue in the City of Chica | | in Abb\ | Vie and | |
| 12/02/20 | Sara Roitman | 0.70 | L160 | A103 | 640.50 |
| | Review and revise position statement for Al | G settlement | discuss | sions. | |
| 12/02/20 | Sara Roitman | 2.00 | L160 | A105 | 1,830.00 |
| | Communicate with Purdue team regarding S Congressional testimony, and implications for | | | • | |
| 12/02/20 | Danielle Gentin Stock | 0.50 | L160 | A105 | 445.00 |
| | Confer internally regarding mediation. | | | | |
| 12/03/20 | Sheila Birnbaum | 0.80 | L160 | A106 | 1,080.00 |
| | Telephone conference with M. Kesselman a settlement issues (0.8). | nd M. Huebn | er rega | rding | |
| 12/03/20 | Sheila Birnbaum | 1.30 | L160 | A108 | 1,755.00 |
| | Telephone conference with MJ White regard telephone conference with representative consettlement (0.8). | _ | | | |
| 12/03/20 | Sara Roitman | 0.70 | L160 | A106 | 640.50 |
| | Confer with client and bankruptcy counsel rand stipulation. | egarding insu | irance s | settlement | |
| 12/03/20 | Sara Roitman | 1.30 | L160 | A108 | 1,189.50 |
| | Confer with third party payors regarding set valuation. | tlement nego | otiation | s and claim | |
| 12/03/20 | Sara Roitman | 0.60 | L160 | A104 | 549.00 |
| | Analyze issues regarding the West Virginia c proposed settlement. | laimants alleg | gations | and | |
| 12/03/20 | Sara Roitman | 0.80 | L160 | A105 | 732.00 |
| | Communicate internally regarding insurance | e settlement a | and stip | oulation. | |
| 12/03/20 | Sara Roitman | 0.70 | L160 | A105 | 640.50 |
| | Communicate with Dechert team regarding negotiations (0.7). | Sackler media | ation a | nd | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 31 of 107

Main Document

Invoice 1010003983 Page 18

| DATE | Тімекеерег | Hours Tas | <u>sk</u> | ACTIVITY | <u>AMOUNT</u> |
|----------|---|---------------|-----------|-----------------|---------------|
| 12/04/20 | Sheila Birnbaum | 1.20 | L160 | A106 | 1,620.00 |
| | Telephone conference with T. Baker and M. issues (0.8); telephone conference with M. k (0.4). | | | = | |
| 12/04/20 | Sheila Birnbaum | 0.80 | L160 | A108 | 1,080.00 |
| | Telephone conference with E. Vonnegut reg telephone conference with mediator regard | _ | | | |
| 12/04/20 | Sara Roitman | 1.20 | L160 | A105 | 1,098.00 |
| | Communicate with Dechert team regarding Sackler mediations. | settlement r | negotiati | ons and | |
| 12/05/20 | Sheila Birnbaum | 0.80 | L160 | A108 | 1,080.00 |
| | Telephone conference with representative c settlement. | of Ad Hoc co | mmittee | regarding | |
| 12/05/20 | Sheila Birnbaum | 0.50 | L160 | A106 | 675.00 |
| | Telephone conference with M. Kesselman re | egarding sett | tlement | issues. | |
| 12/06/20 | Sheila Birnbaum | 1.20 | L160 | A108 | 1,620.00 |
| | Telephone conference with representative of Group, and Davis Polk regarding settlement conference with mediator regarding settlem | term sheet (| | | |
| 12/06/20 | Sheila Birnbaum | 0.30 | L160 | A106 | 405.00 |
| | Telephone conference with M. Kesselman re | egarding sett | tlement. | | |
| 12/07/20 | Sheila Birnbaum | 0.50 | L160 | A104 | 675.00 |
| | Review public health initiative (0.5). | | | | |
| 12/07/20 | Sheila Birnbaum | 0.50 | L160 | A106 | 675.00 |
| | Telephone conference with R. Silbert regard | ing settleme | ent issue | s (0.5). | |
| 12/07/20 | Sara Roitman | 2.30 | L160 | A105 | 2,104.50 |
| | Communicate with Dechert team regarding connection with claim and valuation analysis | | strategy | in | |
| 12/08/20 | Sheila Birnbaum | 0.40 | L160 | A106 | 540.00 |
| | Telephone conference with M. Kesselman re | egarding sett | tlement | issues. | |
| 12/08/20 | Sheila Birnbaum | 1.50 | L160 | A108 | 2,025.00 |
| | Telephone conference with monitor regarding conference with mediators regarding settler | _ | nt (0.5); | telephone | |
| 12/08/20 | Sara Roitman | 0.50 | L160 | A107 | 457.50 |
| | Confer with claimants regarding potential W syndrome claim settlement. | 'est Virginia | neonata | l abstinence | |
| 12/08/20 | Sara Roitman | 0.90 | L160 | A105 | 823.50 |
| | Communicate with Dechert team regarding | Sackler settl | ement n | egotiations. | |
| 12/09/20 | Sheila Birnbaum | 0.80 | L160 | A106 | 1,080.00 |
| | Telephone conference with Purdue regardin telephone conference with M. Kesselman re | _ | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 32 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 19

| DATE | TIMEKEEPER | Hours Tas | <u> </u> | <u>ACTIVITY</u> | AMOUNT |
|----------|---|----------------|------------|-----------------|----------|
| 12/09/20 | Sheila Birnbaum | 1.30 | L160 | A108 | 1,755.00 |
| | Telephone conference with distributor representations (0.8); telephone conference with representative regarding settlement issue (0.5). | | | | |
| 12/09/20 | Sara Roitman | 0.50 | L160 | A107 | 457.50 |
| | Communicate with claimants regarding pote abstinence syndrome claims settlement. | ential West V | /irginia r | neonatal | |
| 12/09/20 | Sara Roitman | 1.40 | L160 | A106 | 1,281.00 |
| | Communicate with Purdue team regarding s negotiations with Sacklers and insurers. | settlement a | nd medi | ation | |
| 12/10/20 | Sheila Birnbaum | 0.50 | L160 | A108 | 675.00 |
| | Telephone conference with monitor regardi | ng settlemer | nt. | | |
| 12/10/20 | Sheila Birnbaum | 0.50 | L160 | A107 | 675.00 |
| | Telephone conference with Purdue and Davissue. | is Polk regar | ding set | tlement | |
| 12/10/20 | Hayden Coleman | 1.10 | L160 | A104 | 1,006.50 |
| | Review and analyze stipulated facts in DOJ paralyze underlying materials regarding same | _ | ent (0.4); | ; review and | |
| 12/10/20 | Sara Roitman | 1.50 | L160 | A104 | 1,372.50 |
| | Review and revise position statement for Al purposes. | G for insurar | nce settle | ement | |
| 12/10/20 | Sara Roitman | 0.70 | L160 | A106 | 640.50 |
| | Communicate with client and insurance cou and insurance negotiations. | nsel regardir | ng AIG p | osition paper | |
| 12/10/20 | Danielle Gentin Stock | 0.30 | L160 | A105 | 267.00 |
| | Correspond internally regarding DOJ settlen | nent papers. | | | |
| 12/11/20 | Sheila Birnbaum | 2.90 | L160 | A108 | 3,915.00 |
| | Telephone conference with mediators regar conference with representatives of consent (0.5); telephone conferences with represent regarding settlement issues (1.4). | ing states reg | garding | settlement | |
| 12/11/20 | Sheila Birnbaum | 0.50 | L160 | A107 | 675.00 |
| | Telephone conference with Davis Polk and F | Purdue regar | ding set | tlement. | |
| 12/11/20 | Sara Roitman | 1.50 | L160 | A107 | 1,372.50 |
| | Review and revise AIG position statement for discussions. | or insurance : | settleme | ent | |
| 12/14/20 | Sheila Birnbaum | 1.80 | L160 | A108 | 2,430.00 |
| | Multiple calls with mediators (0.8); telephor committee regarding settlement (1.0). | ne conferenc | e with A | d Hoc | |

Firm Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.

Filed 02/23/21 Entered 02/23/21 17:59:58

Main Document Pg 33 of 107

Invoice 1010003983 Page 20

| <u>Date</u> | TIMEKEEPER | Hours Task | <u>K</u> | ACTIVITY | AMOUNT | | |
|-------------|--|-----------------|-----------|---------------|----------|--|--|
| 12/14/20 | Sheila Birnbaum | 1.40 | L160 | A106 | 1,890.00 | | |
| | Telephone conference with R. Silbert regarding settlement issues (0.5); telephone conference with Purdue regarding settlement issues (0.5); telephone conference with M. Kesselman regarding settlement (0.4). | | | | | | |
| 12/14/20 | Sara Roitman | 1.00 | L160 | A105 | 915.00 | | |
| | Communicate with Dechert team regarding Congressional testimony. | Sackler media | ation a | nd | | | |
| 12/15/20 | Sheila Birnbaum | 0.50 | L160 | A108 | 675.00 | | |
| | Teleconference with mediator regarding set | tlement. | | | | | |
| 12/15/20 | Sheila Birnbaum | 0.50 | L160 | A106 | 675.00 | | |
| | Telephone conference with T. Baker and M. | Kesselman re | egardin | g settlement. | | | |
| 12/15/20 | Sheila Birnbaum | 0.80 | L160 | A104 | 1,080.00 | | |
| | Review materials on settlement structure (0 |).8). | | | | | |
| 12/16/20 | Sheila Birnbaum | 0.50 | L160 | A106 | 675.00 | | |
| | Telephone conference with Purdue represe issues. | ntatives regar | ding se | ettlement | | | |
| 12/16/20 | Sheila Birnbaum | 1.70 | L160 | A108 | 2,295.00 | | |
| | Telephone conference with representative of claimants regarding settlement (0.7); telephorepresentative of insurance company regard | one conferen | nce with | 1 | | | |
| 12/16/20 | Sheila Birnbaum | 0.80 | | A106 | 1,080.00 | | |
| | Telephone conference with Purdue regardir | ng structure fo | or settle | ement. | | | |
| 12/16/20 | Sheila Birnbaum | 0.50 | L160 | A104 | 675.00 | | |
| | Review emails regarding Multi-state Govern settlement (0.5). | mental Entiti | es Grou | ıp role in | | | |
| 12/16/20 | Jenna Newmark | 0.80 | L160 | A104 | 684.00 | | |
| | Review and analyze term sheet and summa settlement for municipalities (0.8). | ry regarding a | illocatio | on of | | | |
| 12/16/20 | Danielle Gentin Stock | 0.80 | L160 | A105 | 712.00 | | |
| | Correspond internally regarding mediation (| (0.8). | | | | | |
| 12/17/20 | Sheila Birnbaum | 1.20 | L160 | A106 | 1,620.00 | | |
| | Telephone conference with R. Silbert regard telephone conference with M. Kesselman re | _ | | | | | |
| 12/17/20 | Sheila Birnbaum | 1.30 | L160 | A108 | 1,755.00 | | |
| | Telephone conference with mediator regard conference with representative of Ad Hoc or regarding settlement (0.8). | _ | | - | | | |
| 12/17/20 | Sheila Birnbaum | 0.70 | L160 | A104 | 945.00 | | |
| | Review and revise materials regarding settle update (0.7). | ement structu | ire and | government | | | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 21

| DATE | TIMEKEEPER | Hours Tas | <u>sk</u> | ACTIVITY | AMOUNT | | |
|----------|---|----------------|------------|--------------|----------|--|--|
| 12/17/20 | Sara Roitman | 4.20 | L160 | A104 | 3,843.00 | | |
| | Review and analyze Sackler Congressional to implications. | estimony for | settlem | ent | | | |
| 12/18/20 | Sheila Birnbaum | 1.30 | L160 | A108 | 1,755.00 | | |
| | Telephone conference with mediators regarding settlement. | | | | | | |
| 12/18/20 | Sheila Birnbaum | 1.40 | L160 | A106 | 1,890.00 | | |
| | Telephone conference with Purdue regarding settlement issues (0.8); telephone conference with R. Silbert regarding settlement issues (0.6). | | | | | | |
| 12/18/20 | Sheila Birnbaum | 1.00 | L160 | A104 | 1,350.00 | | |
| | Review insurance materials regarding settle from mediators (0.3). | ment (0.7); r | eview m | naterials | | | |
| 12/18/20 | Sheila Birnbaum | 0.70 | L160 | A104 | 945.00 | | |
| | Review materials for settlement structure of | f Purdue (0.7 | 7). | | | | |
| 12/18/20 | Sheila Birnbaum | 0.50 | L160 | A104 | 675.00 | | |
| | Review and respond to emails for Purdue se | ettlement str | ucture (| 0.5). | | | |
| 12/18/20 | Sara Roitman | 1.20 | L160 | A105 | 1,098.00 | | |
| | Communicate Purdue team regarding settle testimony and impact on settlement and m | _ | | | | | |
| 12/19/20 | Sheila Birnbaum | 0.80 | L160 | A108 | 1,080.00 | | |
| | Telephone conference with representatives consenting states regarding settlement. | of Ad Hoc Co | ommitte | ee of | | | |
| 12/20/20 | Sheila Birnbaum | 0.30 | L160 | A106 | 405.00 | | |
| | Telephone conference with M. Heubner reg | arding settle | ment. | | | | |
| 12/20/20 | Sheila Birnbaum | 0.40 | L160 | A107 | 540.00 | | |
| | Telephone conference with Davis Polk regard | rding settlem | ent. | | | | |
| 12/20/20 | Sheila Birnbaum | 0.80 | L160 | A108 | 1,080.00 | | |
| | Telephone conference with mediator regard | ding settleme | ent. | | | | |
| 12/20/20 | Sheila Birnbaum | 0.50 | L160 | A104 | 675.00 | | |
| | Review settlement structure materials (0.5) | | | | | | |
| 12/20/20 | Sara Roitman | 0.50 | L160 | A106 | 457.50 | | |
| | Confer with insurance counsel and client re issue regarding insurance settlement negot | | ance sti | pulation | | | |
| 12/21/20 | Sheila Birnbaum | 1.40 | L160 | A108 | 1,890.00 | | |
| | Multiple telephone conferences with expersettlement structure post-emergence. | ts regarding p | presenta | ation on | | | |
| 12/21/20 | Sheila Birnbaum | 1.30 | L160 | A104 | 1,755.00 | | |
| | Review drafts of settlement structure, post- settlement structure presentation (0.4). | -emergenc (0 |).9); revi | ew emails on | | | |
| 12/22/20 | Sheila Birnbaum | 1.20 | L160 | A107 | 1,620.00 | | |
| | Teleconference with NAACP lawyers regard | ing settlemer | nt issues | S. | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 35 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 22

| <u>Date</u> | TIMEKEEPER | Hours Task | | ACTIVITY | <u>Amount</u> | | |
|-------------|---|-------------------|--------|------------|---------------|--|--|
| 12/22/20 | Sheila Birnbaum | 1.30 L | L160 | A108 | 1,755.00 | | |
| | Telephone conference with Purdue team regarding structural issues of settlement (1.0); telephone conference with mediator regarding settlement issue (0.6); telephone conference with representative of Ad Hoch consenting states regarding settlement (0.7). | | | | | | |
| 12/22/20 | Sheila Birnbaum | 1.50 L | L160 | A106 | 2,025.00 | | |
| | Telephone conference with R. Silbert regard telephone conference with Purdue and T. B. (0.7); telephone conference with M. Kesselr | aker regarding se | ettle | ment issue | | | |
| 12/22/20 | Sheila Birnbaum | 1.00 L | L160 | A104 | 1,350.00 | | |
| | Review and respond to emails regarding set memorandum on outstanding settlement is | | eview | ı | | | |
| 12/22/20 | Sara Roitman | 1.50 L | L160 | A104 | 1,372.50 | | |
| | Review and analyze materials regarding insusettlement discussions. | urance negotiatio | ons a | and | | | |
| 12/22/20 | Sara Roitman | 1.00 L | L160 | A105 | 915.00 | | |
| | Communicate with Dechert team regarding strategy for settlement issues regarding san | | party | payors and | | | |
| 12/22/20 | Sara Roitman | 0.30 L | L160 | A104 | 274.50 | | |
| | Analyze implications for Purdue settlement against co-Defendant regarding suspicious of | | | lawsuit | | | |
| 12/22/20 | Sara Roitman | 0.50 L | L160 | A105 | 457.50 | | |
| | Communicate with Purdue team regarding S | Sackler mediatio | n. | | | | |
| 12/23/20 | Sheila Birnbaum | 0.80 L | L160 | A108 | 1,080.00 | | |
| | Telephone conference with mediator regard | ding settlement. | | | | | |
| 12/23/20 | Sheila Birnbaum | 2.00 L | L160 | A106 | 2,700.00 | | |
| | Discussion with DOJ and Purdue Mediation structure (2.0). | Group regarding | g sett | lement | | | |
| 12/23/20 | Sheila Birnbaum | 1.20 L | L160 | A106 | 1,620.00 | | |
| | Telephone conference with Purdue regardir telephone conference with T. Baker and Pur (0.5). | - | | | | | |
| 12/23/20 | Sheila Birnbaum | 0.50 L | L160 | A104 | 675.00 | | |
| | Review materials on settlement structure an | nd presentation | (0.5) | | | | |
| 12/23/20 | Sheila Birnbaum | 0.60 L | L160 | A107 | 810.00 | | |
| | Telephone call with Purdue team and Davis structure (0.6). | Polk regarding s | ettle | ment | | | |
| 12/23/20 | Sara Roitman | 0.60 L | L160 | A105 | 549.00 | | |
| | Communicate internally regarding mediatio party payors. | n strategy for ob | ojecti | ing third | | | |

Pg 36 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 23

| <u>Date</u> | Тімекеерек | Hours Tasi | <u>K</u> | ACTIVITY | AMOUNT |
|-------------|---|-----------------------------------|-----------------------|--------------------------|------------|
| 12/23/20 | Sara Roitman | 1.10 | L160 | A104 | 1,006.50 |
| | Review and analyze exit proposal for state settlement. | es post-Purdue | confirm | ation and | |
| 12/28/20 | Sheila Birnbaum | 2.60 | L160 | A106 | 3,510.00 |
| | Telephone conference regarding settleme Purdue, and financial experts (1.9); teleph regarding settlement issues (0.7). | | | | |
| 12/29/20 | Sheila Birnbaum | 0.90 | L160 | A108 | 1,215.00 |
| | Telephone conference with representative consenting states regarding settlement. | e of Ad Hoc Cor | mmittee | e of | |
| 12/29/20 | Sheila Birnbaum | 1.90 | L160 | A108 | 2,565.00 |
| | Telephone conferences with mediator reg | garding settleme | ent (1.9 |). | |
| 12/29/20 | Sheila Birnbaum | 1.70 | L160 | A106 | 2,295.00 |
| | Telephone conference with T. Baker and (0.5); telephone conference with M. Kess telephone conference with M. Heubner a issues (0.3); telephone conference with M (0.3). | elman regarding nd Purdue rega | g settlei rding se | ment (0.6); ettlement | |
| 12/29/20 | Sheila Birnbaum | 1.30 | L160 | A104 | 1,755.00 |
| | Review changes to term sheet regarding s issues raised by mediator regarding settle | | cture (0 | .8); review | |
| 12/30/20 | Sheila Birnbaum | 1.40 | L160 | A109 | 1,890.00 |
| | Attend meeting with Purdue Special Com | mittee regardin | g settle | ment. | |
| 12/30/20 | Sheila Birnbaum | 0.40 | L160 | A106 | 540.00 |
| | Telephone conference with R. Silbert rega | arding settleme | nt. | | |
| 12/30/20 | Hayden Coleman | 0.50 | L160 | A105 | 457.50 |
| | Conference call with Dechert team regard issues. | ling mediation ι | updates | and related | |
| L160 SUBTO | TAL HOURS AND FEES: | 103.60 | | | 122,615.50 |
| | | | | | |
| L190 - Othe | r Case Assessment, Development and Admi | nistration | | | |
| 12/03/20 | Jefferson Holder | 0.40 | L190 | A111 | 80.00 |
| | Calendar dates for responses and submiss review status of pending matters (0.2). | sion of legal doc | cuments | s (0.2); | |
| 12/23/20 | Antonella Capobianco-Ranallo | 0.90 | L190 | A101 | 180.00 |
| | Review docket regarding newly filed docuteam leaders regarding same (0.3). | ıments (0.6); co | mmunio | cate with | |
| 12/30/20 | Antonella Capobianco-Ranallo | 0.60 | L190 | A101 | 120.00 |
| | Review docket regarding newly filed docuteam leaders regarding same (0.2). | ıments (0.4); co | mmuni | cate with | |
| L190 SUBTO | TAL HOURS AND FEES: | 1.90 | | | 380.00 |

Firm Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.

Filed 02/23/21 Entered 02/23/21 17:59:58

Main Document Pg 37 of 107

Invoice 1010003983 Page 24

| <u>Date</u> | TIMEKEEPER | Hours Task | <u>ACTIVITY</u> | <u>Amount</u> |
|--------------|--|------------------|---------------------|---------------|
| L210 – Plead | ings | | | |
| 12/01/20 | Hayden Coleman | 0.50 | L210 A104 | 457.50 |
| | Review and analyze amicus brief summited appeal of OK trial verdict (0.5). | by state AGs ir | n opposition to | |
| 12/02/20 | Hayden Coleman | 0.60 | L210 A104 | 549.00 |
| | Review and analyze media's motion to unse | eal (.6). | | |
| 12/02/20 | Jenna Newmark | 0.50 | L210 A104 | 427.50 |
| | Review neonatal abstinence syndrome clas (0.5). | s motion regard | ding claims alleged | |
| 12/02/20 | Danielle Gentin Stock | 0.40 | L210 A105 | 356.00 |
| | Confer internally regarding motion to inter | vene. | | |
| 12/02/20 | Danielle Gentin Stock | 0.40 | L210 A106 | 356.00 |
| | Confer with client regarding motion to inte | rvene (0.4). | | |
| 12/03/20 | Sheila Birnbaum | 0.30 | L210 A104 | 405.00 |
| | Review Physicians for Responsible Opioid P | rescribing cour | t filing. | |
| 12/03/20 | Hayden Coleman | 0.50 | L210 A107 | 457.50 |
| | Communicate with client, DPW and Decher media motion to intervene (0.5). | t team regardir | ng files related to | |
| 12/03/20 | Christopher Boisvert | 0.50 | L210 A104 | 445.00 |
| | Review correspondence related to media's | motion to unse | eal exhibits. | |
| 12/03/20 | Danielle Gentin Stock | 1.10 | L210 A106 | 979.00 |
| | Confer with client (0.5) and internally (0.6) intervene. | regarding medi | ia motion to | |
| 12/03/20 | Jonathan Tam | 0.40 | L210 A104 | 356.00 |
| | Review and analyze states' amicus brief in 0 regarding claims analysis (0.4). | Oklahoma Supr | eme Court Appeal | |
| 12/04/20 | Sarah Magen | 0.40 | L210 A105 | 342.00 |
| | Communicate internally with H. Coleman a of state court orders regarding effect of cor | | | |
| 12/04/20 | Sarah Magen | 1.70 | L210 A104 | 1,453.50 |
| | Review and provide analysis of state court judgment on damages. | orders regardin | g effect of consent | |
| 12/04/20 | Danielle Gentin Stock | 0.50 | L210 A104 | 445.00 |
| | Review material regarding potential neonal motion (0.5). | tal abstinence s | syndrome plaintiff | |
| 12/04/20 | Danielle Gentin Stock | 0.20 | L210 A104 | 178.00 |
| | Review court filings by Non-Consenting Sta | tes (0.2). | | |
| 12/07/20 | Sheila Birnbaum | 0.30 | L210 A104 | 405.00 |
| | Review non-consenting states group staten Intervene (0.3). | nent regarding | Motion to | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 38 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 25

| DATE | TIMEKEEPER | Hours Task | • | ACTIVITY | AMOUNT |
|----------|---|------------------|----------|---------------|----------|
| 12/07/20 | Hayden Coleman | 1.10 | - | A106 | 1,006.50 |
| | Conference call and emails with client and E intervene (1.1). | _ | g media | motion to | 2,000.00 |
| 12/07/20 | Danielle Gentin Stock | 0.80 | L210 | A107 | 712.00 |
| | Confer with co-counsel regarding motion to | intervene. | | | |
| 12/07/20 | Danielle Gentin Stock | 1.40 | L210 | A106 | 1,246.00 |
| | Correspond with client and regarding motio client and internally regarding motion to int | | e (0.8); | confer with | |
| 12/08/20 | Nicholas Dean | 0.50 | L210 | A104 | 182.50 |
| | Analyze proposed documents for pre-trial st | tipulation in W | /.VA. | | |
| 12/08/20 | Danielle Gentin Stock | 0.30 | L210 | A104 | 267.00 |
| | Review filings regarding motion to intervene | e (0.3). | | | |
| 12/08/20 | Danielle Gentin Stock | 0.50 | L210 | A106 | 445.00 |
| | Confer with client regarding motion to inter | vene (0.5). | | | |
| 12/09/20 | Sheila Birnbaum | 2.00 | L210 | A104 | 2,700.00 |
| | Review pleadings regarding Dec. 15 hearing regarding factual issues for hearing (0.8); rescher lawyer (0.5). | | | | |
| 12/10/20 | Sheila Birnbaum | 0.80 | L210 | A104 | 1,080.00 |
| | Review pleadings regarding extension of exc | clusivity (0.8). | | | |
| 12/10/20 | Jonathan Tam | 0.40 | L210 | A104 | 356.00 |
| | Review and analyze Oklahoma's Supreme Co (0.4). | ourt brief rega | ording r | nuisance | |
| 12/11/20 | Sheila Birnbaum | 2.40 | L210 | A104 | 3,240.00 |
| | Review debtor response to claim payment nother filings for December 15 hearing (0.5); complaints to establish a counseling trust (0.5) complaint and confidentiality order (0.8). | review advers | ary pro | oceeding | |
| 12/11/20 | Danielle Gentin Stock | 0.60 | L210 | A104 | 534.00 |
| | Review newly filed pleadings (0.6). | | | | |
| 12/12/20 | Christopher Boisvert | 0.30 | L210 | A103 | 267.00 |
| | Draft correspondence regarding media interdocuments. | rvenors reque | st to ui | nseal certain | |
| 12/14/20 | Sheila Birnbaum | 0.70 | L210 | A104 | 945.00 |
| | Review adversary complaint filed (0.7). | | | | |
| 12/15/20 | Sheila Birnbaum | 1.40 | L210 | A104 | 1,890.00 |
| | Review media stipulation (0.7); review neon motion for discovery and emails regarding s | | ce synd | Irome | |
| 12/15/20 | Danielle Gentin Stock | 0.20 | L210 | A105 | 178.00 |
| | Correspond internally regarding 2004 neona (0.2). | atal abstinence | e syndr | rome Motion | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 39 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 26

| DATE | TIMEKEEPER | Hours Tas | <u> </u> | ACTIVITY | Amount | | | |
|----------|---|---------------|------------|--------------|----------|--|--|--|
| 12/16/20 | Sheila Birnbaum | 1.90 | L210 | A104 | 2,565.00 | | | |
| | Review bankruptcy order regarding motions Hoc committee's motion to unseal (0.6); revidecuments (1.0). | | · - | | | | | |
| 12/16/20 | Hayden Coleman | 2.40 | L210 | A104 | 2,196.00 | | | |
| | Review and analyze neonatal abstinence syndrome Claimants' Rule 2004 Motion and exhibits thereto (2.4). | | | | | | | |
| 12/16/20 | Hope Freiwald | 2.10 | L210 | A104 | 2,289.00 | | | |
| | Reviewing neonatal abstinence syndrome cosupporting documents (2.1). | ommittee's R | Rule 2004 | 1 brief and | | | | |
| 12/16/20 | Hope Freiwald | 1.10 | L210 | A103 | 1,199.00 | | | |
| | Prepare analysis regarding neonatal abstine 2004 brief (1.1). | ence syndrom | ne comm | ittee's Rule | | | | |
| 12/16/20 | Danielle Gentin Stock | 0.20 | L210 | A107 | 178.00 | | | |
| | Confer with co-counsel regarding response syndrome Motion. | to 2004 neon | natal abs | tinence | | | | |
| 12/16/20 | Danielle Gentin Stock | 1.20 | L210 | A103 | 1,068.00 | | | |
| | Research and summarize responses to 2004 motion (1.2). | I neonatal ab | stinence | syndrome | | | | |
| 12/16/20 | Danielle Gentin Stock | 1.70 | L210 | A105 | 1,513.00 | | | |
| | Correspond internally regarding response to syndrome motion (1.7). | o 2004 neona | ital absti | nence | | | | |
| 12/17/20 | Hayden Coleman | 2.90 | L210 | A103 | 2,653.50 | | | |
| | Review and revise opposition to neonatal al (2.9). | bstinence syn | ndrome 2 | 2004 motion | | | | |
| 12/17/20 | Hope Freiwald | 6.50 | L210 | A103 | 7,085.00 | | | |
| | Review and edit brief in response to neonat Claimants rule 2004 motion. | al abstinence | e syndroi | me | | | | |
| 12/17/20 | Danielle Gentin Stock | 7.80 | L210 | A103 | 6,942.00 | | | |
| | Draft (3.5), revise (2.6) and fact-check (1.7) neonatal abstinence syndrome committee r | | oppositio | on to 2004 | | | | |
| 12/17/20 | Danielle Gentin Stock | 0.80 | L210 | A105 | 712.00 | | | |
| | Correspond and confer internally regarding syndrome committee motion response (0.8 | | al abstin | ence | | | | |
| 12/18/20 | Sheila Birnbaum | 2.40 | L210 | A104 | 3,240.00 | | | |
| | Review NAACP memorandum (0.8); review abstinence syndrome Ad Hoc Committee M | | | neonatal | | | | |
| 12/18/20 | Hayden Coleman | 4.50 | L210 | A103 | 4,117.50 | | | |
| | Draft and revise opposition to neonatal abs Rule 2004 motion. | tinence syndr | rome coi | mmittee | | | | |
| 12/18/20 | Hope Freiwald | 6.50 | L210 | A103 | 7,085.00 | | | |
| | Draft and revise Rule 2004 motion response | 2. | | | | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 40 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 27

| <u>Date</u> | Тімекеерег | Hours Tas | <u>sk</u> | <u>ACTIVITY</u> | <u>Amount</u> |
|---------------|---|-----------------------------|----------------------|-----------------|---------------|
| 12/18/20 | Danielle Gentin Stock | 5.90 | L210 | A103 | 5,251.00 |
| | Review and edit response to 2004 neonatal (5.9). | abstinence s | syndrom | e motion | |
| 12/21/20 | Sheila Birnbaum | 2.50 | L210 | A104 | 3,375.00 |
| | Review newly filed pleadings (0.4); review Nof defendants (0.7); review debtors objection syndrome claimants motion to seal (0.5); reproceeding (0.4); review adversary proceed | on to neonata view memor | al abstin andum o | ence | |
| 12/21/20 | Danielle Gentin Stock | 0.70 | L210 | A107 | 623.00 |
| | Confer with co-counsel regarding neonatal a 2004 motion. (0.7). | abstinence sy | yndrome | e Plaintiffs' | |
| 12/21/20 | Danielle Gentin Stock | 0.80 | L210 | A105 | 712.00 |
| | Confer and correspond internally regarding Plaintiffs' 2004 Motion. | neonatal abs | stinence | syndrome | |
| 12/22/20 | Sheila Birnbaum | 1.20 | L210 | A104 | 1,620.00 |
| | Review second motion to intervene by new pleadings (0.6). | s media (0.6) | ; review | newly filed | |
| 12/28/20 | Sheila Birnbaum | 0.80 | L210 | A104 | 1,080.00 |
| | Review draft motion for insurance stipulation | on (0.8). | | | |
| 12/30/20 | Hayden Coleman | 0.20 | L210 | A104 | 183.00 |
| | Review order regarding 6th Circuit rejection review of reversal of class certification orde | - | ' request | t for en banc | |
| 12/30/20 | Paul LaFata | 0.10 | L210 | A104 | 89.00 |
| | Analyze new pleading on automatic stay. | | | | |
| L210 SUBTO | TAL HOURS AND FEES: | 75.90 | | | 78,437.00 |
| L220 – Prelin | ninary Injunctions/Provisional Remedies | | | | |
| 12/09/20 | Danielle Gentin Stock | 0.20 | L220 | A106 | 178.00 |
| | Confer with client regarding injunction quer | y (0.2). | | | |
| 12/10/20 | Danielle Gentin Stock | 0.10 | L220 | A104 | 89.00 |
| | Review correspondence regarding Voluntar | y Injunction | (0.1). | | |
| 12/11/20 | Danielle Gentin Stock | 0.60 | L220 | A103 | 534.00 |
| | Draft summary concerning Voluntary Injunc | tion (0.6). | | | |
| 12/22/20 | Danielle Gentin Stock | 1.50 | L220 | A104 | 1,335.00 |
| | Review and annotate Voluntary Injunction. | | | | |
| 12/23/20 | Danielle Gentin Stock | 0.40 | | A106 | 356.00 |
| | Confer with client regarding review of Volur | | | | |
| 12/23/20 | Danielle Gentin Stock | 1.00 | L220 | A104 | 890.00 |
| | Review and analyze Voluntary Injunction pr | ovisions. | | | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983

Page 28

| DATE | TIMEKEEPER | Hours Ta | <u>sk</u> | ACTIVITY | AMOUNT |
|---------------|--|---------------|------------|----------|----------|
| 12/28/20 | Danielle Gentin Stock | 2.90 | L220 | A103 | 2,581.00 |
| | Draft memorandum related to Voluntary Ingrecommendations (2.9). | junction terr | ns and N | lonitor | |
| 12/29/20 | Danielle Gentin Stock | 1.00 | L220 | A103 | 890.00 |
| | Draft memorandum on Voluntary Injunction | ۱. | | | |
| L220 SUBTOT | AL HOURS AND FEES: | 7.70 | | | 6,853.00 |
| L230 – Court | Mandated Conferences | | | | |
| 12/15/20 | Sheila Birnbaum | 1.50 | L230 | A109 | 2,025.00 |
| | Attend Bankruptcy hearing before Judge Dr. | ain. | | | |
| 12/15/20 | Hayden Coleman | 1.50 | L230 | A109 | 1,372.50 |
| | Prepare for and participate in Purdue Omni | bus Hearing | (1.5). | | |
| 12/15/20 | Paul LaFata | 0.50 | L230 | A109 | 445.00 |
| | Attend court conference on motions related issues. | d to confirma | ation/liti | gation | |
| L230 SUBTO | AL HOURS AND FEES: | 3.50 | | | 3,842.50 |
| | | | | | |
| L310 - Writte | en Discovery | | | | |
| 12/02/20 | Sheila Birnbaum | 0.50 | L310 | A105 | 675.00 |
| | Telephone conference with D. Stock regard | ing discovery | / issues (| 0.5). | |
| 12/03/20 | Jonathan Tam | 0.20 | L310 | A104 | 178.00 |
| | Strategize regarding potential affirmative di objectors (0.2). | scovery in a | nticipatio | on of | |
| 12/08/20 | Sarah Magen | 0.90 | L310 | A102 | 769.50 |
| | Conduct research regarding affirmative disc | overy. | | | |
| 12/10/20 | Sheila Birnbaum | 0.40 | L310 | A104 | 540.00 |
| | Review discovery issues (0.4). | | | | |
| 12/11/20 | Sheila Birnbaum | 1.60 | L310 | A104 | 2,160.00 |
| | Review emails and documents regarding dis documents for discovery and emails regardi | • | | review | |
| 12/15/20 | Sheila Birnbaum | 0.40 | L310 | A105 | 540.00 |
| | Telephone conference with Dechert lawyers | s regarding o | discovery | issue. | |
| 12/16/20 | Sheila Birnbaum | 0.80 | L310 | A104 | 1,080.00 |
| | Review discovery documents and emails (0. | 8). | | | |
| 12/21/20 | Sarah Magen | 0.30 | L310 | A105 | 256.50 |
| | Communicate with S. Roitman regarding thi discovery (.3). | rd party pay | or affirm | native | |
| 12/21/20 | Sarah Magen | 2.80 | L310 | A102 | 2,394.00 |
| | Research regarding third party payor affirm | ative discove | ery. | | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 42 of 107

1 17:59:58 Main Document

Invoice 1010003983 Page 29

| DATE | TIMEKEEPER | Hours Task | | ACTIVITY | Amount | | |
|--------------|--|-------------------|--------|-------------|-----------|--|--|
| 12/22/20 | Sarah Magen | 1.60 | 1310 | A105 | 1,368.00 | | |
| 12,22,20 | Call with D. Gentin-Stock regarding third party payor discovery (.5); call with B. McAneny regarding same (.4); communicate internally with S. Roitman and M. Cusker-Gonzalez regarding same (.7). | | | | | | |
| 12/22/20 | Sarah Magen | 2.80 | L310 | A102 | 2,394.00 | | |
| | Research regarding third party payor discov | ery. | | | | | |
| 12/23/20 | Shmuel Vasser | 0.70 | L310 | A105 | 640.50 | | |
| | Discuss discovery issues with Dechert team. | | | | | | |
| 12/23/20 | Sarah Magen | 1.30 | L310 | A105 | 1,111.50 | | |
| | Communicate with S. Vasser regarding disconnections and D. Gentin-Stock regarding sam | | munic | ate with S. | | | |
| 12/23/20 | Sarah Magen | 1.90 | L310 | A102 | 1,624.50 | | |
| | Research regarding third party claims discov | very. | | | | | |
| 12/23/20 | Danielle Gentin Stock | 1.50 | L310 | A105 | 1,335.00 | | |
| | Confer and correspond internally regarding | discovery (1.5) |). | | | | |
| 12/23/20 | Danielle Gentin Stock | 1.60 | L310 | A104 | 1,424.00 | | |
| | Review and analyze discovery and court filir | ngs regarding th | he san | ne. | | | |
| 12/29/20 | Sheila Birnbaum | 0.70 | L310 | A104 | 945.00 | | |
| | Review discovery documents and emails (0. | 7). | | | | | |
| 12/30/20 | Sarah Magen | 0.50 | L310 | A107 | 427.50 | | |
| | Call with Davis Polk regarding discovery issu | ies. | | | | | |
| L310 SUBTO | FAL HOURS AND FEES: | 20.50 | | | 19,863.00 | | |
| L320 – Docui | nent Production | | | | | | |
| 12/01/20 | Hayden Coleman | 1.70 | L320 | A104 | 1,555.50 | | |
| | Review and analyze non-consenting states a UCC Motion to Compel Production of privile thereto (1.7). | | | • • | | | |
| 12/01/20 | Paul LaFata | 0.40 | L320 | A106 | 356.00 | | |
| | Confer with client and counsel regarding dis | scovery strateg | у. | | | | |
| 12/02/20 | Christopher Boisvert | 4.20 | L320 | A103 | 3,738.00 | | |
| | Review documents previously produced in a to intervene (2.8); summarize same (1.4). | all jurisdictions | regard | ding motion | | | |
| 12/03/20 | Hayden Coleman | 2.20 | L320 | A104 | 2,013.00 | | |
| | Review files related to media motion to inte | ervene (2.2). | | | | | |
| 12/03/20 | Sarah Magen | 0.80 | L320 | A104 | 684.00 | | |
| | Review documents regarding discovery requ | uests. | | | | | |
| 12/03/20 | Danielle Gentin Stock | 0.90 | L320 | A104 | 801.00 | | |
| | Review documents regarding motion to inte correspondence related to contract language | | view a | and analyze | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 43 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 30

| DATE | TIMEKEEPER | Hours Tas | <u>sk</u> <u>/</u> | ACTIVITY | Amount |
|----------|--|---------------|--------------------|-------------|----------|
| 12/03/20 | Paul LaFata | 0.30 | L320 A | \104 | 267.00 |
| | Analyze supplemental document production | n in Africano | (IL). | | |
| 12/07/20 | Hayden Coleman | 3.20 | L320 A | \104 | 2,928.00 |
| | Review and analyze documents subject to m | nedia motion | n to interve | ene (3.2). | |
| 12/07/20 | Christopher Boisvert | 0.50 | L320 A | \104 | 445.00 |
| | Review sealed exhibits subject to media ent | ities' motion | to unseal. | | |
| 12/07/20 | Danielle Gentin Stock | 0.40 | L320 A | \104 | 356.00 |
| | Review materials related to motion to interv | vene. | | | |
| 12/07/20 | Paul LaFata | 0.40 | L320 A | \107 | 356.00 |
| | Confer with non-party counsel (0.2) and co-document production and protective order. | | nsel (0.2) r | egarding | |
| 12/07/20 | Paul LaFata | 0.20 | L320 A | \102 | 178.00 |
| | Research response to document production | and protect | tive order (| (0.2). | |
| 12/08/20 | Hayden Coleman | 0.50 | L320 A | \105 | 457.50 |
| | Conference call with Dechert team regarding subject to media motion to unseal (0.5). | g review of s | sealed doc | uments | |
| 12/08/20 | Hayden Coleman | 3.10 | L320 A | \104 | 2,836.50 |
| | Review and analyze sealed documents subjection (2.7); review and comment on sealing review | | | unseal | |
| 12/08/20 | Christopher Boisvert | 7.50 | L320 A | \104 | 6,675.00 |
| | Confidentiality review of documents sought media entities. | to be unsea | led by inte | ervenor | |
| 12/08/20 | Christopher Boisvert | 0.60 | L320 A | \105 | 534.00 |
| | Telephone conference with D. Gentin Stock sought to be unsealed by media entity inter- | | eview of do | ocuments | |
| 12/08/20 | Danielle Gentin Stock | 1.40 | L320 A | \105 | 1,246.00 |
| | Correspond internally regarding documents | at issue in m | notion to i | ntervene. | |
| 12/08/20 | Danielle Gentin Stock | 0.60 | L320 A | \104 | 534.00 |
| | Review correspondence and materials relate | ed to motion | n to interve | ene (0.6). | |
| 12/09/20 | Sheila Birnbaum | 0.70 | L320 A | \104 | 945.00 |
| | Review discovery materials (0.7). | | | | |
| 12/09/20 | Hayden Coleman | 1.50 | L320 A | \104 | 1,372.50 |
| | Review documents pertinent to media motion | on to unseal | (1.5). | | |
| 12/09/20 | Christopher Boisvert | 5.70 | L320 A | \104 | 5,073.00 |
| | Confidentiality review of documents sought media intervenors. | to be remov | ved from s | eal by | |
| 12/09/20 | Christopher Boisvert | 0.50 | L320 A | \105 | 445.00 |
| | Telephone conference with D. Gentin Stock, discuss review of documents sought to be reintervenors. | - | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 44 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 31

| DATE | TIMEKEEPER | Hours Tas | <u>sk</u> | ACTIVITY | AMOUNT |
|----------|---|---------------|------------|-----------------|----------|
| 12/09/20 | Danielle Gentin Stock | 4.90 | L320 | A104 | 4,361.00 |
| | Review and analyze sealed documents (4.2); prior ruling and respond to client query (0.7) | _ | ation his | tory for | |
| 12/09/20 | Danielle Gentin Stock | 0.30 | L320 | A105 | 267.00 |
| | Confer internally regarding document review | ٧. | | | |
| 12/09/20 | Michelle Yeary | 2.30 | L320 | A104 | 2,047.00 |
| | Review documents for recommendations on (2.3). | confidentia | ality and | unsealing | |
| 12/09/20 | Michelle Yeary | 0.40 | L320 | A105 | 356.00 |
| | Telephone call with D. Stock, C. Boisvert and materials for potential unsealing (.4). | H. Coleman | n regardi | ng review of | |
| 12/10/20 | Hayden Coleman | 0.60 | L320 | A107 | 549.00 |
| | Coordinate with DPW and Dechert teams rev Media motion to unseal. | viewing doc | uments s | subject to | |
| 12/10/20 | Christopher Boisvert | 5.00 | L320 | A104 | 4,450.00 |
| | Confidentiality review of documents sought intervenors. | to be unsea | led by m | edia | |
| 12/10/20 | Danielle Gentin Stock | 2.00 | L320 | A104 | 1,780.00 |
| | Review documents and proposed summaries | s for client. | | | |
| 12/10/20 | Michelle Yeary | 4.00 | L320 | A104 | 3,560.00 |
| | Review documents from motion to intervene | e for confide | entiality. | | |
| 12/11/20 | Christopher Boisvert | 0.30 | L320 | A105 | 267.00 |
| | Telephone conference with D. Gentin-Stock of documents sought to be unsealed by med | | | iality review | |
| 12/11/20 | Danielle Gentin Stock | 1.40 | L320 | A105 | 1,246.00 |
| | Correspond internally regarding status and s | cope of doc | ument re | eview. | |
| 12/11/20 | Paul LaFata | 0.20 | L320 | A107 | 178.00 |
| | Confer with local counsel regarding protective | ve order inq | uiry (NJ) | | |
| 12/11/20 | Paul LaFata | 0.70 | L320 | A107 | 623.00 |
| | Confer with co-defense counsel (0.4) and no request for production of documents and in | | | | |
| 12/11/20 | Michelle Yeary | 3.50 | L320 | A104 | 3,115.00 |
| | Review documents sought to be unsealed by confidentiality (3.5). | / media inte | rvenors | for | |
| 12/14/20 | Sheila Birnbaum | 0.80 | L320 | A104 | 1,080.00 |
| | Review discovery issues and documents (0.8 |). | | | |
| 12/14/20 | Christopher Boisvert | 5.30 | L320 | A104 | 4,717.00 |
| | Confidentiality review of documents sought intervenors. | to be unsea | led by m | edia | |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 32

| <u>Date</u> | <u>Timekeeper</u> | Hours Tas | <u>K</u> | ACTIVITY | Amount |
|-------------|---|------------------|-----------|-------------|----------|
| 12/14/20 | Paul LaFata | 0.40 | L320 | A106 | 356.00 |
| | Confer with client discovery team regarding productions. | g discovery pr | ojects a | nd | |
| 12/14/20 | Paul LaFata | 0.10 | L320 | A107 | 89.00 |
| | Confer with non-party counsel regarding de | ocument prod | luction. | | |
| 12/14/20 | Michelle Yeary | 4.30 | L320 | A104 | 3,827.00 |
| | Review documents sought to be unsealed I confidentiality (4.3). | by media inter | rvenors | for | |
| 12/15/20 | Hayden Coleman | 0.40 | L320 | A105 | 366.00 |
| | Conference call with Dechert team regarding upcoming trials. | ng document s | stipulat | ions for | |
| 12/15/20 | Hayden Coleman | 0.60 | L320 | A104 | 549.00 |
| | Review and comment on analysis of documuseal (0.6). | nents subject t | to Medi | a motion to | |
| 12/15/20 | Christopher Boisvert | 6.60 | L320 | A104 | 5,874.00 |
| | Review documents sought to be unsealed I | by media inter | venors. | | |
| 12/15/20 | Paul LaFata | 0.50 | L320 | A107 | 445.00 |
| | Confer with co-defense counsel (0.4) and n production of documents and information. | | nsel (0.1 |) regarding | |
| 12/15/20 | Michelle Yeary | 6.30 | L320 | A104 | 5,607.00 |
| | Analyze documents for potential unsealing | (6.3). | | | |
| 12/15/20 | Michelle Yeary | 0.70 | L320 | A105 | 623.00 |
| | Discuss key issues with C. Boisvert regarding unsealing (.7). | ng documents | for pote | ential | |
| 12/16/20 | Christopher Boisvert | 3.70 | L320 | A104 | 3,293.00 |
| | Review documents sought to be unsealed I | by media inter | venors | (3.7). | |
| 12/16/20 | Christopher Boisvert | 2.20 | L320 | A103 | 1,958.00 |
| | Prepare analysis regarding documents soug intervenors (2.2). | ght to be unse | aled by | media | |
| 12/16/20 | Paul LaFata | 0.30 | L320 | A107 | 267.00 |
| | Confer with non-party counsel (0.2) and co document production from non-party. | -defense coun | nsel (0.1 |) regarding | |
| 12/16/20 | Michelle Yeary | 6.00 | L320 | A104 | 5,340.00 |
| | Review and analyze documents for potenti | al unsealing (6 | 5.0). | | |
| 12/16/20 | Michelle Yeary | 0.50 | L320 | A105 | 445.00 |
| | Call with C. Boisvert regarding next steps in | n confidentialit | ty revie | w (.5). | |
| 12/17/20 | Christopher Boisvert | 6.10 | L320 | A104 | 5,429.00 |
| | Confidentiality review of documents sough intervenors. | t to be unseal | ed by m | nedia | |
| 12/17/20 | Michelle Yeary | 5.00 | L320 | A104 | 4,450.00 |
| | Review and analyze documents for possible | e unsealing. | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 46 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 33

| DATE | TIMEKEEPER | Hours Tasi | <u>K</u> | ACTIVITY | <u>Amount</u> | | |
|----------|--|----------------|-----------|-----------------|---------------|--|--|
| 12/18/20 | Christopher Boisvert | 0.20 | L320 | A104 | 178.00 | | |
| | Review correspondence from co-counsel regarding documents sought to be unsealed by the UCC and media intervenors. | | | | | | |
| 12/18/20 | Michelle Yeary | 4.00 | L320 | A104 | 3,560.00 | | |
| | Review and analyze of documents for possib | ole unsealing. | | | | | |
| 12/21/20 | Hayden Coleman | 2.20 | L320 | A104 | 2,013.00 | | |
| | Review and analyze documents subject to M | ledia motion | to unse | eal (2.2). | | | |
| 12/21/20 | Christopher Boisvert | 2.20 | L320 | A104 | 1,958.00 | | |
| | Review documents sought to be unsealed by | y media inter | venors. | | | | |
| 12/21/20 | Michelle Yeary | 3.00 | L320 | A104 | 2,670.00 | | |
| | Review and analyze documents for possible | unsealing. | | | | | |
| 12/22/20 | Hayden Coleman | 0.60 | L320 | A106 | 549.00 | | |
| | Communicate with client, Dechert and DPW documents subject to media motion to unse | _ | ling revi | iew of | | | |
| 12/22/20 | Christopher Boisvert | 5.00 | L320 | A104 | 4,450.00 | | |
| | Confidentiality review of documents sought intervenors. | to be unseal | ed by m | nedia | | | |
| 12/22/20 | Christopher Boisvert | 0.50 | L320 | A107 | 445.00 | | |
| | Telephone conference with co-counsel to dis outstanding documents subject to media int | | | | | | |
| 12/22/20 | Michelle Yeary | 3.90 | | A104 | 3,471.00 | | |
| | Review and analyze documents for possible Boisvert regarding same (.4). | unsealing (3. | .5); call | with C. | | | |
| 12/22/20 | Michelle Yeary | 0.50 | L320 | A107 | 445.00 | | |
| | Teleconference with Davis Polk regarding stakey issues for redaction (.5) | atus of confic | dentialit | ty review and | | | |
| 12/23/20 | Hayden Coleman | 2.00 | L320 | A106 | 1,830.00 | | |
| | Prepare for and participate in conference ca regarding confidential designations of certai with client regarding same (1.2). | | | | | | |
| 12/23/20 | Christopher Boisvert | 3.00 | L320 | A104 | 2,670.00 | | |
| | Confidentiality review of documents sought intervenors. | to be unseal | ed by m | nedia | | | |
| 12/23/20 | Paul LaFata | 0.20 | L320 | A107 | 178.00 | | |
| | Confer with co-defense counsel regarding pr vendor agreement. | roposed revis | sions to | document | | | |
| 12/23/20 | Paul LaFata | 0.40 | L320 | A107 | 356.00 | | |
| | Confer with co-counsel (0.3) and non-party or protective order and document production. | counsel (0.1) | regardi | ing | | | |
| 12/23/20 | Michelle Yeary | 1.80 | L320 | A104 | 1,602.00 | | |
| | Review documents for confidentiality (1.8). | | | | | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 47 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 34

| DATE | TIMEKEEPER | Hours TA | <u>ASK</u> | ACTIVITY | <u>Amount</u> |
|--------------|--|------------------|-------------|-----------------|---------------|
| 12/23/20 | Michelle Yeary | 0.60 | L320 | A105 | 534.00 |
| | Email with C. Boisvert regarding same rev confidentiality (.3); follow up call with C. E | | | steps (.3). | |
| 12/23/20 | Michelle Yeary | 0.70 | L320 | A106 | 623.00 |
| | Participate in call with client regarding co | nfidentiality re | eview (.7) |). | |
| 12/24/20 | Paul LaFata | 0.10 | L320 | A107 | 89.00 |
| | Confer with non-party counsel regarding of | document pro | duction. | | |
| 12/26/20 | Christopher Boisvert | 5.50 | L320 | A104 | 4,895.00 |
| | Confidentiality review of documents soug intervenors. | ht to be unse | aled by m | nedia | |
| 12/27/20 | Christopher Boisvert | 2.70 | L320 | A104 | 2,403.00 |
| | Confidentiality review of documents soug intervenors. | ht to be unse | aled by m | nedia | |
| 12/28/20 | Sheila Birnbaum | 0.50 | L320 | A104 | 675.00 |
| | Review emails regarding discovery privileg | ge issue (0.5). | | | |
| 12/30/20 | Christopher Boisvert | 7.50 | L320 | A104 | 6,675.00 |
| | Confidentiality review of documents soug intervenors. | ht to be unse | aled by m | nedia | |
| 12/31/20 | Christopher Boisvert | 0.40 | L320 | A106 | 356.00 |
| | Telephone conference with client to discu of documents sought to be unsealed by m | | | ality review | |
| 12/31/20 | Christopher Boisvert | 0.90 | L320 | A104 | 801.00 |
| | Confidentiality review of documents soug intervenors. | ht to be unse | aled by m | nedia | |
| 12/31/20 | Michelle Yeary | 2.00 | L320 | A104 | 1,780.00 |
| | Review documents subject to motion to u | nseal for conf | fidentialit | y redactions | |
| L320 SUBTO | TAL HOURS AND FEES: | 163.10 | | | 146,516.00 |
| L330 – Depo | sitions | | | | |
| 12/02/20 | Hayden Coleman | 0.70 | L330 | A104 | 640.50 |
| | Review final transcript of R. Sackler depos | ition and exh | ibits there | eto (.7). | |
| 12/18/20 | Shmuel Vasser | 3.50 | L330 | A104 | 3,202.50 |
| | Review various discovery pleadings. | | | | |
| L330 SUBTO | TAL HOURS AND FEES: | 4.20 | | | 3,843.00 |
| L350 – Disco | very Motions | | | | |
| 12/04/20 | Sheila Birnbaum | 0.70 | L350 | A104 | 945.00 |
| | Review proposed motion for discovery by group (0.7). | neonatal abs | tinence s | yndrome | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 48 of 107

Main Document

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 35

| DATE | TIMEKEEPER | Hours T | ASK | ACTIVITY | Amount |
|---------------|---|------------------------------------|--------------------------|--------------|----------|
| 12/07/20 | Sheila Birnbaum | 0.80 | | A107 | 1,080.00 |
| ,, | Telephone conference with Purdue, Dav discovery issues (0.8). | | | _ | 2,000.00 |
| 12/08/20 | Sheila Birnbaum Review discovery motions (0.7). | 0.70 | L350 | A104 | 945.00 |
| L350 SUBTOT | AL HOURS AND FEES: | 2.20 | | | 2,970.00 |
| L390 – Other | Discovery | | | | |
| 12/14/20 | Hayden Coleman | 0.30 | L390 | A105 | 274.50 |
| | Emails with Dechert team regarding J. Ri | | | | |
| 12/17/20 | Shmuel Vasser | 2.00 | | A104 | 1,830.00 |
| | Review various discovery issues (2.0). | | | | |
| L390 SUBTOT | AL HOURS AND FEES: | 2.30 | | | 2,104.50 |
| | | | | | |
| L410 – Fact W | /itnesses | | | | |
| 12/01/20 | Hayden Coleman | 0.90 | L410 | A107 | 823.50 |
| | Conferences with WilmerHale regarding Congressional hearing. | background m | naterials fo | or potential | |
| 12/01/20 | Hayden Coleman | 4.50 | L410 | A106 | 4,117.50 |
| | Conference calls and emails with client repotential Congressional hearing (2.4); particle other outside counsel regarding same (1). WebEx with client regarding updates and | rticipate in W .1); plan for ar | ebEx with nd particip | client and | |
| 12/01/20 | Hayden Coleman | 1.80 | L410 | A104 | 1,647.00 |
| | Review and comment on background management (1.8). | aterials for pot | ential Cor | ngressional | |
| 12/01/20 | Sarah Magen | 0.40 | L410 | A105 | 342.00 |
| | Communicate internally regarding prepa | ration of C. La | ndau testi | mony. | |
| 12/01/20 | Sarah Magen | 3.70 | L410 | A104 | 3,163.50 |
| | Review and analyze materials in prepara | tion of C. Lanc | dau testim | ony (3.7). | |
| 12/01/20 | Danielle Gentin Stock | 3.00 | L410 | A106 | 2,670.00 |
| | Communicate with client regarding pote (2.3); review materials in advance of call. | • | s before C | ongress | |
| 12/01/20 | Danielle Gentin Stock | 0.40 | L410 | A104 | 356.00 |
| | Review draft materials for potential Con | gressional hea | ring. | | |
| 12/01/20 | Antonella Capobianco-Ranallo | 0.40 | L410 | A102 | 80.00 |
| | Prepare C. Landau appearance materials | | | | |
| 12/02/20 | Sheila Birnbaum | 1.60 | L410 | A104 | 2,160.00 |
| | Review materials on Landau testimony ((0.8)). | 0.8); review de | eposition t | estimony | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 49 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 36

| <u>Date</u> | TIMEKEEPER | Hours Tas | <u>sk</u> | ACTIVITY | AMOUNT |
|-------------|--|----------------------------------|-----------|-----------|----------|
| 12/02/20 | Hayden Coleman | 2.20 | L410 | A104 | 2,013.00 |
| | Review and comment on preparation mater (2.2). | ial for Congr | essional | inquiries | |
| 12/02/20 | Sarah Magen | 0.30 | L410 | A104 | 256.50 |
| | Review materials for C. Landau preparation. | | | | |
| 12/02/20 | Sarah Magen | 0.30 | L410 | A105 | 256.50 |
| | Communicate internally regarding materials | for C. Landa | au repar | ation. | |
| 12/02/20 | Danielle Gentin Stock | 2.90 | L410 | A106 | 2,581.00 |
| | Confer with client regarding draft Q&As for review drafts and related correspondence (Opreparation for potential Congressional heat correspondence regarding the same (0.6). | 0.5); confer v | with clie | | |
| 12/08/20 | Sheila Birnbaum | 1.20 | L410 | A104 | 1,620.00 |
| | Review deposition transcripts of C. Landau a | and J. White | (1.2). | | |
| 12/08/20 | Hayden Coleman | 1.80 | L410 | A104 | 1,647.00 |
| | Review transcripts of C. Landau deposition (| 1.8). | | | |
| 12/08/20 | Hayden Coleman | 0.30 | L410 | A106 | 274.50 |
| | Communicate with client regarding Congres | sional hearir | ngs (0.3) | • | |
| 12/09/20 | Hayden Coleman | 1.60 | L410 | A106 | 1,464.00 |
| | Communicate with client and retained coun Congressional hearing (1.6). | sel regarding | g prepar | ation for | |
| 12/09/20 | Sarah Magen | 0.50 | L410 | A105 | 427.50 |
| | Communicate internally regarding issues for | r C. Landau t | estimon | у. | |
| 12/09/20 | Sarah Magen | 1.40 | L410 | A104 | 1,197.00 |
| | Review and analyze issues for C. Landau tes | timony. | | | |
| 12/10/20 | Hayden Coleman | 2.40 | L410 | A107 | 2,196.00 |
| | Conference call with WilmerHale, client, and regarding preparation for Congressional heat correspondence with WilmerHale, client and regarding materials for Congressional hearing | aring (0.5); co d other retai | onferenc | ces and | |
| 12/10/20 | Hayden Coleman | 5.40 | L410 | A104 | 4,941.00 |
| | Review and analyze transcripts and pleading preparation for Congressional hearing (3.2); preparation materials for Congressional hea | review and | | | |
| 12/10/20 | Sarah Magen | 0.40 | L410 | A102 | 342.00 |
| | Research for C. Landau testimony. | | | | |
| 12/11/20 | Hayden Coleman | 3.00 | L410 | A108 | 2,745.00 |
| | Plan for and participate in WebEx Congressi | onal hearing | prepara | ation. | |
| 12/11/20 | Hayden Coleman | 2.70 | L410 | A104 | 2,470.50 |
| | Review and comment on revised outlines ar Congressional hearing. | nd preparatio | on mate | rials for | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 50 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 37

| DATE | TIMEKEEPER | Hours Tas | <u>sk</u> | ACTIVITY | Amount |
|----------|--|----------------|-----------|---------------|----------|
| 12/11/20 | Sarah Magen | 0.40 | L410 | A102 | 342.00 |
| | Research regarding C. Landau testimony. | | | | |
| 12/12/20 | Sarah Magen | 0.50 | L410 | A103 | 427.50 |
| | Prepare analysis for C. Landau testimony. | | | | |
| 12/14/20 | Sheila Birnbaum | 0.80 | L410 | A104 | 1,080.00 |
| | Review materials for Congressional hearing | (0.8). | | | |
| 12/14/20 | Hayden Coleman | 3.10 | L410 | A104 | 2,836.50 |
| | Review and revise Congressional hearing pr and revise written testimony for Congression | | | (2.2); review | |
| 12/14/20 | Hayden Coleman | 3.00 | L410 | A101 | 2,745.00 |
| | Prepare for and participate in preparation for client and other outside counsel (3.0). | or Congression | onal hea | ring with | |
| 12/14/20 | Hayden Coleman | 1.20 | L410 | A106 | 1,098.00 |
| | Emails and telephone conference with clien regarding preparation for Congressional hea | | retained | counsel | |
| 12/14/20 | Paul LaFata | 0.40 | L410 | A107 | 356.00 |
| | Confer with co-counsel regarding deposition advice on public statements (0.4). | n record in su | upport o | f client | |
| 12/14/20 | Paul LaFata | 1.80 | L410 | A104 | 1,602.00 |
| | Analyze deposition record in support of clie (1.8). | nt advice on | public st | tatements | |
| 12/15/20 | Hayden Coleman | 3.70 | L410 | A109 | 3,385.50 |
| | Participate in Congressional hearing WebEx | preparation | (3.7) | | |
| 12/15/20 | Hayden Coleman | 2.40 | L410 | A104 | 2,196.00 |
| | Review and comment on revised Q&A and retestimony (1.1); review and revise draft writers. | | _ | - | |
| 12/16/20 | Sheila Birnbaum | 0.40 | L410 | A104 | 540.00 |
| | Review statements for Congressional hearing | ng (0.4). | | | |
| 12/16/20 | Hayden Coleman | 0.90 | L410 | A104 | 823.50 |
| | Review and comment on written testimony finalize preparation materials for Congression | _ | | earing (.2); | |
| 12/16/20 | Hayden Coleman | 1.40 | L410 | A106 | 1,281.00 |
| | Participate in WebEx with client and co-cou Congressional hearing. | nsel regardir | ng prepa | ration for | |
| 12/16/20 | Hayden Coleman | 1.20 | L410 | A105 | 1,098.00 |
| | Emails and conference call with Dechert tea scientific and medical arguments in Congres | | - | ding to | |
| 12/17/20 | Hayden Coleman | 0.60 | L410 | A105 | 549.00 |
| | Conference call with Dechert team regardin Congressional Hearing. | g follow up i | tems fro | om | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 51 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 38

| <u>Date</u> | TIMEKEEPER | Hours Task | | <u>ACTIVITY</u> | <u>Amount</u> |
|--------------|---|------------------|---------|-----------------|---------------|
| 12/17/20 | Hayden Coleman | 0.50 | L410 | A106 | 457.50 |
| | Conference call with client and retained cou Hearing regarding Purdue's sales practices. | ınsel regarding | Congi | ressional | |
| 12/17/20 | Hayden Coleman | 1.00 | L410 | A103 | 915.00 |
| | Prepare materials for Congressional Hearing practices (1.0). | g regarding Pui | rdue's | sales | |
| 12/17/20 | Mara Cusker Gonzalez | 0.80 | L410 | A104 | 732.00 |
| | Review labeling chronology summary in pre Congressional testimony. | paration for co | ompan | У | |
| 12/17/20 | Mara Cusker Gonzalez | 0.40 | L410 | A107 | 366.00 |
| | Confer with litigation counsel regarding laber preparation for company Congressional test | | gy sum | mary in | |
| 12/17/20 | Jenna Newmark | 2.50 | L410 | A104 | 2,137.50 |
| | Review file for materials for Congressional h | nearing (2.5). | | | |
| 12/17/20 | Danielle Gentin Stock | 3.70 | L410 | A104 | 3,293.00 |
| | Review and summarize Congressional testing | nony (3.7). | | | |
| 12/17/20 | Danielle Gentin Stock | 0.60 | L410 | A105 | 534.00 |
| | Confer internally regarding Congressional horizontal (0.6). | earing and oth | er wor | kstreams | |
| L410 SUBTOT | AL HOURS AND FEES: | 74.40 | | | 68,586.00 |
| | | | | | |
| L440 – Other | Trial Preparation and Support | | | | |
| 12/01/20 | Paul LaFata | 0.20 | L440 | A106 | 178.00 |
| | Confer with client regarding pretrial stipulat | tion. | | | |
| 12/08/20 | Paul LaFata | 2.20 | L440 | A104 | 1,958.00 |
| | Analyze proposed documents for pretrial sti revisions to stipulation (2.2). | ipulation on do | ocume | nts with | |
| 12/08/20 | Paul LaFata | 0.50 | L440 | A108 | 445.00 |
| | Confer with client (0.3) and opposing couns pretrial stipulation. | el (0.2) regardi | ing rev | isions to | |
| 12/09/20 | Paul LaFata | 0.60 | L440 | A104 | 534.00 |
| | Analyze documents for pretrial stipulation (0.2). | 0.4); draft revi | sions t | o stipulation | |
| 12/09/20 | Paul LaFata | 0.50 | L440 | A107 | 445.00 |
| | Confer with client (0.3) and co-defense cour pretrial stipulation. | nsel (0.2) regar | ding r | evisions to | |
| 12/10/20 | Paul LaFata | 0.10 | L440 | A106 | 89.00 |
| | Confer with client regarding pretrial stipulat | tion on docum | ents. | | |
| 12/11/20 | Paul LaFata | 0.40 | L440 | A106 | 356.00 |
| | Confer with client regarding document anal stipulation. | ysis and strate | gy for | pretrial | |

19-23649-shl Doc 2412

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 52 of 107

Main Document

Invoice 1010003983 Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Page 39

| <u>Date</u> | <u>TIMEKEEPER</u> | Hours TA | SK | <u>ACTIVITY</u> | <u>Amount</u> |
|--|--|--|---|-------------------------------|--|
| 12/14/20 | Paul LaFata | 0.60 | L440 | A107 | 534.00 |
| | Confer with co-counsel (0.4) and p stipulation. | laintiffs' counsel (0.2) |) regardin | g pretrial | |
| 12/14/20 | Paul LaFata | 0.20 | L440 | A103 | 178.00 |
| | Draft revisions to pretrial stipulation | on (0.2). | | | |
| 12/15/20 | Paul LaFata | 0.40 | L440 | A107 | 356.00 |
| | Confer with co-counsel regarding s | trategy for pretrial st | ipulation | (0.4). | |
| 12/18/20 | Paul LaFata | 0.20 | L440 | A106 | 178.00 |
| | Confer with client regarding pretric | al stipulation. | | | |
| 12/22/20 | Paul LaFata | 0.90 | L440 | A103 | 801.00 |
| | Draft revisions to pretrial stipulations same (0.4). | on (0.3); analyze docu | ıments re | garding | |
| LAAO CUDTO | TAL HOURS AND EFFS: | 6.80 | | | 6,052.00 |
| L440 SUBTO | TAL HOURS AND FEES: | 6.80 | | | 0,002.00 |
| L440 SUBTO | TAL HOURS AND FEES: | 0.80 | | | 3,002.00 |
| | and Hearing Attendance | 0.80 | | | 3,332.33 |
| | | 3.00 | L450 | A109 | · |
| L450 – Trial | and Hearing Attendance | 3.00 Is hearing and follow | -up regar | ding same | 2,745.00 |
| L450 – Trial | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omnibu regarding Sackler mediations and p | 3.00 Is hearing and follow | -up regard | ding same | · |
| L450 – Trial a | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omniburegarding Sackler mediations and process. | 3.00 Is hearing and follow- privilege requests and 1.90 | -up regard | ding same firmation | 2,745.00 |
| L450 – Trial a | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omnibu regarding Sackler mediations and p process. Danielle Gentin Stock | 3.00 Is hearing and follow- privilege requests and 1.90 | up regare d plan cor L450 | ding same firmation | 2,745.00 |
| L450 – Trial a 12/15/20 12/15/20 | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omniburegarding Sackler mediations and process. Danielle Gentin Stock Attend virtual bankruptcy hearing. | 3.00 Is hearing and follow- privilege requests and 1.90 3.70 | -up regard d plan cor L450 | ding same firmation | 2,745.00 1,691.00 |
| L450 – Trial a 12/15/20 12/15/20 | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omnibu regarding Sackler mediations and process. Danielle Gentin Stock Attend virtual bankruptcy hearing. Sheila Birnbaum | 3.00 Is hearing and follow- privilege requests and 1.90 3.70 | -up regard d plan cor L450 L450 cklers. | ding same firmation | 2,745.00 1,691.00 4,995.00 |
| L450 - Trial a 12/15/20 12/15/20 12/17/20 | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omniburegarding Sackler mediations and process. Danielle Gentin Stock Attend virtual bankruptcy hearing. Sheila Birnbaum Attend Congressional hearing rega | 3.00 Is hearing and follow- privilege requests and 1.90 3.70 rding Purdue and Sac | L450 L450 L450 L450 L450 | ding same firmation A109 A109 | 2,745.00 1,691.00 |
| L450 - Trial a 12/15/20 12/15/20 12/17/20 12/17/20 | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omniburegarding Sackler mediations and process. Danielle Gentin Stock Attend virtual bankruptcy hearing. Sheila Birnbaum Attend Congressional hearing regated | 3.00 Is hearing and follow- privilege requests and 1.90 3.70 rding Purdue and Sac | L450 L450 L450 L450 L450 | ding same firmation A109 A109 | 2,745.00 1,691.00 4,995.00 |
| L450 - Trial a 12/15/20 12/15/20 12/17/20 12/17/20 | and Hearing Attendance Sara Roitman Attend Purdue bankruptcy omniburegarding Sackler mediations and process. Danielle Gentin Stock Attend virtual bankruptcy hearing. Sheila Birnbaum Attend Congressional hearing regathayden Coleman Attend Congressional Hearing regathayden | 3.00 Is hearing and follow- privilege requests and 1.90 3.70 Irding Purdue and Sacons 3.70 Irding Purdue's sales | L450 L450 L450 L450 L450 | ding same firmation A109 A109 | 2,745.00 1,691.00 4,995.00 3,385.50 |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 53 of 107

Invoice 1010003983

Main Document

Page 40

| TIMEKEEPER SUMMARY: | | | | | | | |
|-----------------------|-----------------|----------|--------------|----------------|--|--|--|
| TIMEKEEPER | TITLE | RATE | <u>Hours</u> | <u>Amount</u> | | | |
| S. Birnbaum | Partner | 1,350.00 | 143.50 | 193,725.00 | | | |
| H. Freiwald | Partner | 1,090.00 | 17.00 | 18,530.00 | | | |
| H. Coleman | Partner | 915.00 | 113.10 | 103,486.50 | | | |
| M. Cusker Gonzalez | Partner | 915.00 | 12.80 | 11,712.00 | | | |
| S. Roitman | Partner | 915.00 | 78.90 | 72,193.50 | | | |
| E. Snapp | Partner | 915.00 | 0.50 | 457.50 | | | |
| S. Vasser | Partner | 915.00 | 9.70 | 8,875.50 | | | |
| S. Magen | Associate | 855.00 | 48.20 | 41,211.00 | | | |
| B. McAnaney | Associate | 855.00 | 0.00 | 0.00 | | | |
| J. Newmark | Associate | 855.00 | 21.50 | 18,382.50 | | | |
| L. Zanello | Associate | 800.00 | 0.30 | 240.00 | | | |
| N. Dean | Staff Attorney | 365.00 | 0.50 | 182.50 | | | |
| C. Boisvert | Counsel | 890.00 | 76.90 | 68,441.00 | | | |
| L. Cohan | Counsel | 890.00 | 1.00 | 890.00 | | | |
| D. Gentin Stock | Counsel | 890.00 | 90.20 | 80,278.00 | | | |
| P. LaFata | Counsel | 890.00 | 17.50 | 15,575.00 | | | |
| J. Tam | Counsel | 890.00 | 13.10 | 11,659.00 | | | |
| M. Yeary | Counsel | 890.00 | 49.50 | 44,055.00 | | | |
| A. Capobianco-Ranallo | Legal Assistant | 200.00 | 3.50 | 700.00 | | | |
| J. Holder | Legal Assistant | 200.00 | 0.40 | 80.00 | | | |
| M. Stone | Legal Assistant | 200.00 | 0.30 | 60.00 | | | |
| TOTALS | | | 698.40 | USD 690,734.00 | | | |
| | | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003983

Firm Client Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.

Matter Name: Mediation & Settlement, Claims Evaluation, and Operations

Electronic Billing Number: 20210003064

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 552,838.58

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003983) in the check memo. Mail to: Dechert LLP \mid P.O. Box 7247-6643 Philadelphia, PA \mid 19170-6643



Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003982

Firm Client Matter Number: 399631.178406

Client Name: Purdue Pharma L.P.

Matter Name: Fee Applications and Related Expenses

Electronic Billing Number: 20190002705

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 27,810.50 |
|-----------------------------------|---------------|
| Less 20% Discount | (5,562.10) |
| NET TOTAL FEES THIS INVOICE | 22,248.40 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 22,248.40 |

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Pg 56 of 107

Invoice 1010003982 Page 2

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

| <u>Date</u> | TIMEKEEPER | Hours Task | | <u>ACTIVITY</u> | <u>AMOUNT</u> |
|--------------|--|--------------------|----------|-----------------|---------------|
| B160 - Fee/E | mployment Applications | | | | |
| 12/01/20 | Katherine Norman | 1.30 | B160 | A103 | 734.50 |
| | Review and revise Dechert October time en | ntries (1.3). | | | |
| 12/01/20 | Matthew Stone | 3.40 | B160 | A103 | 680.00 |
| | Review and edit October time entries to co | e guidelines. | | | |
| 12/02/20 | Hayden Coleman | 0.40 | B160 | A104 | 366.00 |
| | Review letter from fee examiner and relate | d exhibits. | | | |
| 12/02/20 | Shmuel Vasser | 1.50 | B160 | A104 | 1,372.50 |
| | Review fee examiner's report regarding into | erim fee appli | cation. | | |
| 12/02/20 | Shmuel Vasser | 1.00 | B160 | A105 | 915.00 |
| | Emails to Dechert team regarding issues to report (0.4); discuss, review issues with IP t application (0.6). | | | | |
| 12/02/20 | Katherine Norman | 0.40 | B160 | A105 | 226.00 |
| | Call with B. Stone regarding Dechert Octobe emails from S. Vasser and H. Coleman regar | | | | |
| 12/02/20 | Katherine Norman | 2.90 | B160 | A103 | 1,638.50 |
| | Review and revise Dechert October time en | ntries (2.9). | | | |
| 12/02/20 | Matthew Stone | 2.30 | B160 | A104 | 460.00 |
| | Review Ankura status and invoices regardin communicate with S. Vasser regarding same | _ | er objec | ction (1.9); | |
| 12/03/20 | Shmuel Vasser | 0.50 | B160 | A105 | 457.50 |
| | Emails with Dechert team regarding fee exa | aminer issues. | | | |
| 12/03/20 | Matthew Stone | 5.50 | B160 | A103 | 1,100.00 |
| | Review and edit October time entries to co | nform to U.S. | Trustee | e guidelines. | |
| 12/04/20 | Hayden Coleman | 0.50 | B160 | A108 | 457.50 |
| | Call with fee examiner regarding interim fee | e application | (0.5). | | |
| 12/04/20 | Hayden Coleman | 0.60 | B160 | A104 | 549.00 |
| | Review fee examiner's letter regarding billing | ng inquiries. | | | |
| 12/04/20 | Hayden Coleman | 0.40 | B160 | A105 | 366.00 |
| | Communicate internally regarding fee exam | niner's billing | questio | ns (0.4). | |
| 12/04/20 | Shmuel Vasser | 3.10 | B160 | A103 | 2,836.50 |
| | Review and revise October invoice (Multi D | istrict Litigation | on) (3.1 |). | |
| 12/04/20 | Shmuel Vasser | 1.00 | | A108 | 915.00 |
| | Prepare response to fee examiner's report regarding same (0.5). | (0.5); call with | n fee ex | aminer | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 57 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406

Page 3

Invoice 1010003982

| <u>Date</u> | Тімекеерек | Hours | TASK | <u>ACTIVITY</u> | AMOUNT |
|-------------|--|--------------|--------------|-----------------|----------|
| 12/04/20 | Katherine Norman | 0.20 | B160 | A105 | 113.00 |
| | Email with S. Vasser, H. Coleman and B. Stoinvoices and fee applications (.2). | ne regardi | ing Decher | t October | |
| 12/04/20 | Matthew Stone | 5.40 | B160 | A103 | 1,080.00 |
| | Review and edit October time entries to cor | nform to U | J.S. Trustee | guidelines. | |
| 12/04/20 | Matthew Stone | 0.60 | B160 | A105 | 120.00 |
| | Communicate with C. Norman (.3) and S. Va statement. | isser (.3) r | egarding O | ctober fee | |
| 12/05/20 | Matthew Stone | 2.50 | B160 | A103 | 500.00 |
| | Review and edit October time entries to cor | nform to L | J.S. Trustee | guidelines. | |
| 12/07/20 | Matthew Stone | 3.40 | B160 | A103 | 680.00 |
| | Review and edit October time entries to cor | nform to L | J.S. Trustee | guidelines. | |
| 12/08/20 | Shmuel Vasser | 0.10 | B160 | A108 | 91.50 |
| | Emails with fee examiner regarding interim | fee applic | cation. | | |
| 12/08/20 | Shmuel Vasser | 0.20 | B160 | A105 | 183.00 |
| | Internal emails regarding monthly fee state | ment. | | | |
| 12/08/20 | Katherine Norman | 0.20 | B160 | A105 | 113.00 |
| | Email correspondence with B. Stone and I. C November invoice (.2). | Campos re | garding De | chert | |
| 12/08/20 | Matthew Stone | 2.10 | B160 | A103 | 420.00 |
| | Review and edit October time entries to cor | nform to L | J.S. Trustee | guidelines. | |
| 12/08/20 | Matthew Stone | 0.40 | B160 | A105 | 80.00 |
| | Communicate with D. Gentin-Stock regarding | ng Octobe | r time entr | ies. | |
| 12/09/20 | Shmuel Vasser | 2.40 | B160 | A103 | 2,196.00 |
| | Review and revise Municipalities October in | voice. | | | |
| 12/09/20 | Shmuel Vasser | 0.40 | B160 | A108 | 366.00 |
| | Emails with fee examiner regarding issue re | solution. | | | |
| 12/09/20 | Katherine Norman | 0.10 | B160 | A105 | 56.50 |
| | Email correspondence with S. Vasser and B. application (.1). | Stone reg | garding Dec | hert fee | |
| 12/09/20 | Matthew Stone | 1.10 | B160 | A103 | 220.00 |
| | Review and edit November time entries to oguidelines. | conform to | o U.S. Trust | tee | |
| 12/10/20 | Shmuel Vasser | 0.50 | B160 | A105 | 457.50 |
| | Emails with Dechert team regarding time er | ntries. | | | |
| 12/10/20 | Matthew Stone | 4.40 | B160 | A103 | 880.00 |
| | Review and edit October (1.4) and Novemboto U.S. Trustee guidelines. | er (3.0) tin | me entries | to conform | |
| 12/10/20 | Matthew Stone | 0.70 | B160 | A105 | 140.00 |
| | Communicate internally regarding October | fee staten | ment. | | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 58 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406 Invoice 1010003982

Page 4

| DATE | Тімекеерег | Hours TA | <u>ASK</u> | ACTIVITY | AMOUNT | | |
|----------|---|----------------|-------------|-----------------|----------|--|--|
| 12/11/20 | Shmuel Vasser | 0.20 | B160 | A105 | 183.00 | | |
| | Emails internally regarding notice of fee incr | ease. | | | | | |
| 12/11/20 | Shmuel Vasser | 0.30 | B160 | A105 | 274.50 | | |
| | Emails with Dechert team regarding October fees. | | | | | | |
| 12/11/20 | Katherine Norman | 0.40 | B160 | A105 | 226.00 | | |
| | Review emails regarding Dechert rates (.2) a | nd Octobei | r fee state | ement (.2). | | | |
| 12/11/20 | Matthew Stone | 3.80 | B160 | A103 | 760.00 | | |
| | Review and edit October time entries to con | form to U.S | S. Trustee | guidelines. | | | |
| 12/14/20 | Matthew Stone | 0.40 | B160 | A105 | 80.00 | | |
| | Communicate with H. Coleman regarding sta (.3) and interim fee application (.1) | atus of mor | nthly fee s | statement | | | |
| 12/14/20 | Matthew Stone | 1.90 | B160 | A103 | 380.00 | | |
| | Review and edit October (.8) and November to U.S. Trustee guidelines. | (1.1) fee st | tatement | s to conform | | | |
| 12/15/20 | Shmuel Vasser | 0.30 | B160 | A104 | 274.50 | | |
| | Review draft fee order for 3rd interim applic | ations. | | | | | |
| 12/15/20 | Shmuel Vasser | 0.30 | B160 | A105 | 274.50 | | |
| | Emails with Dechert team regarding fee hea | ring. | | | | | |
| 12/15/20 | Matthew Stone | 0.30 | B160 | A105 | 60.00 | | |
| | Communicate with S. Vasser regarding inter | im fee orde | er. | | | | |
| 12/15/20 | Matthew Stone | 1.60 | B160 | A103 | 320.00 | | |
| | Review and edit October fee statement to coguidelines. | onform to l | J.S. Trust | ee | | | |
| 12/16/20 | Shmuel Vasser | 1.10 | B160 | A103 | 1,006.50 | | |
| | Review and revise October fee statement. | | | | | | |
| 12/16/20 | Shmuel Vasser | 0.40 | B160 | A105 | 366.00 | | |
| | Email with Dechert team regarding fee state | ment comr | ments, ra | tes. | | | |
| 12/16/20 | Matthew Stone | 0.50 | B160 | A105 | 100.00 | | |
| | Communicate with S. Vasser (.3) and H. Cole statement. | eman (.2) re | egarding (| October fee | | | |
| 12/16/20 | Matthew Stone | 4.00 | B160 | A103 | 800.00 | | |
| | Draft and revise October fee statement (3.6) bankruptcy court (.2) and serve same (.2). |); file fee st | atement | with | | | |
| 12/18/20 | Matthew Stone | 2.80 | B160 | A103 | 560.00 | | |
| | Review and edit November invoices to confo | orm to U.S. | Trustee g | guidelines. | | | |
| 12/30/20 | Matthew Stone | 0.30 | B160 | A105 | 60.00 | | |
| | Communicate internally regarding objection statement and status of fee statement. | deadline fo | or Octobe | er fee | | | |
| 12/31/20 | Matthew Stone | 2.00 | B160 | A103 | 400.00 | | |
| | Review and edit November invoices to confo | orm to U.S. | Trustee g | guidelines. | | | |

19-23649-shl Doc 2412

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 59 of 107

Main Document

Invoice 1010003982 Page 5

| <u>Date</u> | TIMEKEEPER | Hours | <u>Task</u> | <u>ACTIVITY</u> | Amount |
|--------------|--|--------|-------------|-----------------|---------------|
| B160 SUBTO | TAL HOURS AND FEES: | 70.10 | | | 26,895.50 |
| | | | | | |
| B165 – Budge | eting (case) | | | | |
| 12/02/20 | Shmuel Vasser | 1.00 | B165 | A104 | 915.00 |
| | Review 2021 fees, budget and related i | ssues. | | | |
| B165 SUBTO | TAL HOURS AND FEES: | 1.00 | | | 915.00 |
| | | | | | |
| | | | | | |
| TOTAL HOUR | S AND FEES | 71.10 | | | USD 27,810.50 |
| | | | | | |

| TIMEKEEPER SUMMARY: | | | | | | |
|---------------------|-----------------|--------------|--------------|---------------|--|--|
| TIMEKEEPER | <u>Title</u> | <u> Rate</u> | <u>Hours</u> | AMOUNT | | |
| H. Coleman | Partner | 915.00 | 1.90 | 1,738.50 | | |
| S. Vasser | Partner | 915.00 | 14.30 | 13,084.50 | | |
| K. Norman | Associate | 565.00 | 5.50 | 3,107.50 | | |
| M. Stone | Legal Assistant | 200.00 | 49.40 | 9,880.00 | | |
| TOTALS | | | 71.10 | USD 27,810.50 | | |
| | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For guestions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003982

Firm Client Matter Number: 399631.178406

Client Name: Purdue Pharma L.P.

Matter Name: Fee Applications and Related Expenses

Electronic Billing Number: 20190002705

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 22,248.40

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003982) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003984

Firm Client Matter Number: 399631.161942

Client Name: Purdue Pharma L.P. Matter Name: Municipality Suits

Electronic Billing Number: 20170001582

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 28,978.00 |
|-----------------------------------|---------------|
| Less 20% Discount | (5,795.60) |
| NET TOTAL FEES THIS INVOICE | 23,182.40 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 23,182.40 |

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942 Filed 02/23/21 Entered 02/23/21 17:59:58

Main Document Pg 62 of 107

Invoice 1010003984 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

| <u>Date</u> | Тімекеерег | Hours TA | SK ACTIVITY | AMOUNT |
|--------------|---|----------------|----------------------|--------|
| L120 - Analy | sis/Strategy | | | |
| 12/17/20 | Hayden Coleman | 0.70 | L120 A104 | 640.50 |
| | Review and analyze Tennessee Supreme (0.7). | Court decision | in Effler vs. Purdue | |
| 12/21/20 | Danielle Gentin Stock | 0.30 | L120 A104 | 267.00 |
| | Review analysis of NY State litigation. | | | |
| L120 SUBTO | TAL HOURS AND FEES: | 1.00 | | 907.50 |
| L190 – Other | Case Assessment, Development and Admi | inistration | | |
| 12/02/20 | Denise Neris | 0.50 | L190 A101 | 77.50 |
| | Monitor, review, and summarize new ple coordinated litigation and communicate same. | | | |
| 12/03/20 | Denise Neris | 1.00 | L190 A101 | 155.00 |
| | Monitor, review, and summarize new ple coordinated litigation and communicate same. | _ | = | |
| 12/09/20 | Denise Neris | 1.00 | L190 A101 | 155.00 |
| | Monitor, review, and summarize new ple coordinated litigation and communicate same. | _ | = | |
| 12/10/20 | Denise Neris | 0.50 | L190 A101 | 77.50 |
| | Monitor, review, and summarize new ple coordinated litigation and communicate same. | _ | = | |
| 12/11/20 | Denise Neris | 1.00 | L190 A101 | 155.00 |
| | Monitor, review, and summarize new ple coordinated litigation and communicate same. | _ | = | |
| 12/14/20 | Denise Neris | 1.00 | L190 A101 | 155.00 |
| | Monitor, review, and summarize new ple coordinated litigation and communicate same. | _ | _ | |
| 12/15/20 | Denise Neris | 1.00 | L190 A101 | 155.00 |
| | Monitor, review, and summarize new ple coordinated litigation and communicate same. | _ | _ | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 63 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942 Invoice 1010003984

Page 3

| DATE | TIMEKEEPER | Hours Tas | <u> </u> | ΑςτινιτΥ | Amount |
|---------------|---|---------------|-------------|------------|----------|
| 12/16/20 | Denise Neris | 1.00 | L190 | A101 | 155.00 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | _ | | _ | |
| 12/17/20 | Denise Neris | 1.00 | L190 | A101 | 155.00 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | | | | |
| 12/18/20 | Denise Neris | 1.00 | L190 | A101 | 155.00 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | _ | | _ | |
| 12/21/20 | Denise Neris | 1.00 | L190 | A101 | 155.00 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | • | | _ | |
| 12/23/20 | Denise Neris | 1.00 | L190 | A101 | 155.00 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | _ | | _ | |
| 12/28/20 | Denise Neris | 0.50 | L190 | A101 | 77.50 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | _ | | _ | |
| 12/29/20 | Denise Neris | 0.50 | L190 | A101 | 77.50 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | _ | | _ | |
| 12/30/20 | Denise Neris | 0.50 | L190 | A101 | 77.50 |
| | Monitor, review, and summarize new plead coordinated litigation and communicate wit same. | _ | | _ | |
| L190 SUBTOT | TAL HOURS AND FEES: | 12.50 | | | 1,937.50 |
| L210 – Pleadi | ngs | | | | |
| 12/01/20 | Sheila Birnbaum | 0.70 | L210 | A104 | 945.00 |
| | Review motions in NY for separate trials (0. | 7). | | | |
| 12/01/20 | Alyssa Clark | 0.70 | L210 | A104 | 507.50 |
| | Summarize Counties' Motion to Disjoin for t | team (0.7, NY | ′). | | |
| 12/17/20 | Bert Wolff | 0.30 | L210 | A104 | 274.50 |
| | Review TN Supreme Court Effler decision di | smissing AG's | s claims | (0.3, TN). | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 64 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942 Invoice 1010003984

Page 4

| DATE | TIMEKEEPER | Hours Ta | .SK | ACTIVITY | Amount |
|--------------|---|---------------|-------------|-----------------|----------|
| 12/18/20 | Alyssa Clark | 1.10 | L210 | A104 | 797.50 |
| | Review and summarize motion for summary | judgment (| (1.1, NY). | | |
| 12/18/20 | Jenna Newmark | 0.60 | L210 | A104 | 513.00 |
| | Review summary of New York state defendation judgment (0.6). | ınts' motion | for sum | mary | |
| 12/21/20 | Hayden Coleman | 0.60 | L210 | A104 | 549.00 |
| | Review Defendants' motion for summary judand related emails (0.6). | dgment of N | NY Plainti | ffs' claims | |
| 12/21/20 | Mara Cusker Gonzalez | 0.80 | L210 | A103 | 732.00 |
| | Draft summary of recent motion filings and Stewardship Act. | rulings rega | rding NY | Opioid | |
| 12/29/20 | Lindsay Zanello | 0.70 | L210 | A105 | 560.00 |
| | Communicate internally regarding motion to (.7). | intervene | in West \ | /irginia case | |
| 12/29/20 | Lindsay Zanello | 0.20 | L210 | A104 | 160.00 |
| | Review motion to intervene in West Virginia | case (.2). | | | |
| 12/29/20 | Lindsay Zanello | 0.20 | L210 | A107 | 160.00 |
| | Communicate with bankruptcy counsel rega West Virginia case (.2). | rding motio | n to inte | rvene in | |
| 12/29/20 | Christopher Boisvert | 1.00 | L210 | A104 | 890.00 |
| | Review request to unseal McCallister (West record. | Virginia stat | te court (| class action) | |
| L210 SUBTOT | AL HOURS AND FEES: | 6.90 | | | 6,088.50 |
| | | | | | |
| L320 – Docum | nent Production | | | | |
| 12/23/20 | Sheila Birnbaum | 0.70 | L320 | A104 | 945.00 |
| | Review discovery privilege issues and emails | regarding s | same (0.7 | '). | |
| 12/28/20 | Hayden Coleman | 2.20 | L320 | A104 | 2,013.00 |
| | Review media motion and exhibits to unseal WV). | l in McCallis | ter case | (Putnam Cty, | |
| 12/28/20 | Hayden Coleman | 1.90 | L320 | A107 | 1,738.50 |
| | Conferences and emails with DPW, client, ar response to media motion and exhibits to ur Cty, WV). | | | | |
| 12/28/20 | Christopher Boisvert | 1.60 | L320 | A104 | 1,424.00 |
| | Confidentiality review of documents sought intervenors. | to be unsea | aled by m | edia | |
| 12/28/20 | Michelle Yeary | 4.00 | L320 | A104 | 3,560.00 |
| | Review documents for confidentiality and pe | ossible unse | ealing (4.0 | 0). | |

19-23649-shl Doc 2412

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 65 of 107

Main Document

Invoice 1010003984 Page 5

| <u>Date</u> | TIMEKEEPER | Hours Tas | <u> Ас</u> | TIVITY | AMOUNT |
|---------------|---|-----------------------|----------------|--------|----------------|
| 12/28/20 | Michelle Yeary | 0.30 | L320 A1 | .05 | 267.00 |
| | Emails with C. Boisvert and H. Colema West Virginia case file (.3). | n regarding media | request to | unseal | |
| 12/29/20 | Hayden Coleman | 1.60 | L320 A1 | .06 | 1,464.00 |
| | Conferences and correspondence wit regarding media motion to unseal WV | | Dechert tea | ms | |
| 12/29/20 | Christopher Boisvert | 3.10 | L320 A1 | 04 | 2,759.00 |
| | Confidentiality review of documents sintervenors. | sought to be unsea | led by media | a | |
| 12/29/20 | Paul LaFata | 0.30 | L320 A1 | .07 | 267.00 |
| | Confer with non-party counsel (0.2) a production of non-party documents a | | regarding | | |
| 12/29/20 | Michelle Yeary | 4.50 | L320 A1 | 04 | 4,005.00 |
| | Review and analyze documents for counseal (4.5). | onfidentiality regard | ding motion | to | |
| 12/29/20 | Michelle Yeary | 0.40 | L320 A1 | 05 | 356.00 |
| | Email with team regarding confidentiate to intervene (.4). | ality review in conn | ection with | motion | |
| 12/30/20 | Michelle Yeary | 1.00 | L320 A1 | 04 | 890.00 |
| | Review client comments on confident continuing analysis. | iality redactions ar | nd apply to | | |
| L320 SUBTOT | AL HOURS AND FEES: | 21.60 | | | 19,688.50 |
| L520 – Appell | ate Briefs | | | | |
| 12/17/20 | Jonathan Tam | 0.40 | L520 A1 | 04 | 356.00 |
| | Review and analyze Tennessee Supre | me Court decision i | in Effler (0.4 | , TN). | |
| L520 SUBTOT | AL HOURS AND FEES: | 0.40 | | | 356.00 |
| TOTAL LICUS | S AND FEEG | 42.40 | | | 1150 20 070 22 |
| TOTAL HOUR | S AND FEES | 42.40 | | | USD 28,978.00 |

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942 Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 66 of 107

Main Document

Invoice 1010003984 Page 6

| Timekeeper Summary: | | | | | | | | |
|---------------------|-------------------|--------------|-------|---------------|--|--|--|--|
| TIMEKEEPER | <u>Title</u> | <u> Rате</u> | Hours | Amount | | | | |
| S. Birnbaum | Partner | 1,350.00 | 1.40 | 1,890.00 | | | | |
| H. Coleman | Partner | 915.00 | 7.00 | 6,405.00 | | | | |
| M. Cusker Gonzalez | Partner | 915.00 | 0.80 | 732.00 | | | | |
| B. Wolff | Partner | 915.00 | 0.30 | 274.50 | | | | |
| J. Newmark | Associate | 855.00 | 0.60 | 513.00 | | | | |
| L. Zanello | Associate | 800.00 | 1.10 | 880.00 | | | | |
| A. Clark | Associate | 725.00 | 1.80 | 1,305.00 | | | | |
| C. Boisvert | Counsel | 890.00 | 5.70 | 5,073.00 | | | | |
| D. Gentin Stock | Counsel | 890.00 | 0.30 | 267.00 | | | | |
| P. LaFata | Counsel | 890.00 | 0.30 | 267.00 | | | | |
| J. Tam | Counsel | 890.00 | 0.40 | 356.00 | | | | |
| M. Yeary | Counsel | 890.00 | 10.20 | 9,078.00 | | | | |
| D. Neris | Project Assistant | 155.00 | 12.50 | 1,937.50 | | | | |
| TOTALS | | | 42.40 | USD 28,978.00 | | | | |
| | | | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003984

Firm Client Matter Number: 399631.161942

Client Name: Purdue Pharma L.P. Matter Name: Municipality Suits

Electronic Billing Number: 20170001582

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 23,182.40

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003984) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003985

Firm Client Matter Number: 399630.163596

Client Name: Purdue Pharma L.P.

Matter Name: COSTS ONLY - Joint Defense Group Expense Billing Matter

Electronic Billing Number: 20180002029 or 20180002094

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 88,723.47

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

19-23649-shl Doc 2412

Client Name: Purdue Pharma L.P. Firm Matter Number: 399630.163596

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 69 of 107

Main Document

Invoice 1010003985 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

| DESCRIPTION | <u>AMOUNT</u> |
|---|---------------|
| Consultants Fees Consultants Fees - VENDOR: Ankura Consulting Group, LLC INVOICE NO. CI-023333 12/10/20 For November 2020 services | 182.19 |
| Consultants Fees - VENDOR: Ankura Consulting Group, LLC Invoice#: CI-024260; Date: 12/21/2020 For November 2020 Services | 88,541.28 |
| | 88,723.47 |
| TOTAL DISBURSEMENTS | USD 88,723.47 |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 23, 2021 Invoice Number 1010003985

Firm Client Matter Number: 399630.163596

Client Name: Purdue Pharma L.P.

Matter Name: COSTS ONLY - Joint Defense Group Expense Billing Matter

Electronic Billing Number: 20180002029 or 20180002094

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 88,723.47

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003985) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003986

Firm Client Matter Number: 379612.156278

Client Name: Purdue Pharma L.P.

Matter Name: (477C1) (13-MP-0017US03) Reduction of Alpha, Beta-Unsaturated Ketone Levels in Morphinan

Derivative

Electronic Billing Number: 20170001301

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 3,214.12 |
|-----------------------------------|--------------|
| TOTAL DISBURSEMENTS THIS INVOICE | 260.00 |
| NET TOTAL FEES THIS INVOICE | 2,954.12 |
| Less 8% Discount | (256.88) |
| TOTAL FEES THIS INVOICE | 3,211.00 |

Payment by Wire or ACH

Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.156278

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document

Pg 72 of 107

Invoice 1010003986 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

| <u>Date</u> | TIMEKEEPER | Hours Task | <u> </u> | ACTIVITY | <u>Amount</u> |
|----------------|--|---------------------|----------|-----------------|---------------|
| P260 – Intelle | ectual Property | | | | |
| 12/15/20 | Sherrice Breland | 0.40 | P260 | A104 | 114.00 |
| | Study newly received Final Office Action (0.2); organize prosecution history (0.1). | (0.1); prepare pe | ending o | claim set | |
| 12/15/20 | Sherrice Breland | 0.50 | P260 | A106 | 142.50 |
| | Prepare letter to client regarding Final Of | fice Action (0.5) | ī | | |
| 12/15/20 | Sherrice Breland | 0.20 | P260 | A105 | 57.00 |
| | Discuss Final Office Action with B. Hackm | an (0.2). | | | |
| 12/16/20 | Sherrice Breland | 0.30 | P260 | A104 | 85.50 |
| | Review correspondence from Maiwald at associated with related Australian patent letter and attachment (0.1). | - | • | | |
| 12/23/20 | Blaine Hackman | 1.50 | P260 | A104 | 1,110.00 |
| | Review Final Office Action (0.8); prepare W. Yang (0.7). | an analysis of th | e Office | Action for | |
| 12/30/20 | Blaine Hackman | 2.30 | P260 | A104 | 1,702.00 |
| | Analyze the Office Action regarding poter | ntial strategies fo | or respo | onse. | |
| P260 SUBTO | TAL HOURS AND FEES: | 5.20 | | | 3,211.00 |
| | | | | | |
| TOTAL HOUF | RS AND FEES | 5.20 | | | USD 3,211.00 |
| | | | | | |

| TIMEKEEPER SUMMARY: | | | | | | | |
|---------------------|-----------------|-------------|--------------|---------------|--|--|--|
| TIMEKEEPER | <u>Title</u> | <u>Rate</u> | <u>Hours</u> | <u>Amount</u> | | | |
| B. Hackman | Associate | 740.00 | 3.80 | 2,812.00 | | | |
| S. Breland | Legal Assistant | 285.00 | 1.40 | 399.00 | | | |
| TOTALS | | | 5.20 | USD 3,211.00 | | | |
| | | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For guestions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003986

Firm Client Matter Number: 379612.156278

Client Name: Purdue Pharma L.P.

Matter Name: (477C1) (13-MP-0017US03) Reduction of Alpha, Beta-Unsaturated Ketone Levels in Morphinan

Derivative

Electronic Billing Number: 20170001301

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 3,214.12

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003986) in the check memo. Mail to: Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003987

Firm Client Matter Number: 379612.165623

Client Name: Purdue Pharma L.P.

Matter Name: (502US) (18-MT-0001US02) Sleep Disorder Treatment and Prevention

Electronic Billing Number: 20190002322

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 2,803.92 |
|-----------------------------------|--------------|
| TOTAL DISBURSEMENTS THIS INVOICE | 779.00 |
| NET TOTAL FEES THIS INVOICE | 2,024.92 |
| Less 8% Discount | (176.08) |
| TOTAL FEES THIS INVOICE | 2,201.00 |

Payment by Wire or ACH

Firm Matter Number: 379612.165623

Client Name: Purdue Pharma L.P.

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 75 of 107

23/21 17:59:58 Main Document

Invoice 1010003987 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

| DATE | TIMEKEEPER | Hours TA | <u>SK</u> <u>ACTIVITY</u> | <u>Amount</u> |
|---------------|--|---|--|---------------|
| P260 – Intell | ectual Property | | | |
| 12/01/20 | Blaine Hackman | 0.20 | P260 A105 | 148.00 |
| | Review 3.73 Statement and related filing | papers. | | |
| 12/01/20 | Blaine Hackman | 0.10 | P260 A105 | 74.00 |
| | Correspond with S. Breland regarding pov filings (0.1). | ver of attorney | y and assignment | |
| 12/01/20 | Sherrice Breland | 1.50 | P260 A103 | 427.50 |
| | Study file (0.1); organize prosecution histor prepare draft 3.73 Statement and transm Attorney (0.3); finalize; file and upload 3.7 and Transmittal for submission of Power and Trademark Office Electronic Filing System (0.1); file and uploat and Trademark Office Electronic Patent A organization of prosecution history (0.1). | ittal for submi 73 Statement, of Attorney wi stem (0.5); pre ad assignments | ssion of Power of Power of Attorney th the U.S. Patent pare documents for s with the U.S. Patent | |
| 12/01/20 | Sherrice Breland | 0.70 | P260 A106 | 199.50 |
| | Prepare draft letter to client regarding fili Disclosure Statement and related docume letter, information disclosure statement a (0.2). | ents (0.5); final | lize and forward | |
| 12/01/20 | Sherrice Breland | 0.20 | P260 A105 | 57.00 |
| | Discuss letter with B. Hackman (0.1); discussive with B. Hackman (0.1). | uss assignmen | ts being recorded | |
| 12/01/20 | Erin Peacock | 0.20 | P260 A110 | 49.00 |
| | Review Response to Notice of Insufficience Amendment filed with the United States I note same in calendar database (0.1). | - | | |
| 12/02/20 | Erin Peacock | 0.20 | P260 A110 | 49.00 |
| | Review Power of Attorney and 3.73 State Patent and Trademark Office (0.1); note s | | | |
| 12/03/20 | Sherrice Breland | 0.40 | P260 A103 | 114.00 |
| | Study file, filed Power of Attorney and 3.7 prosecution history and correspondence | | 0.1); organize | |
| 12/03/20 | Sherrice Breland | 0.60 | P260 A106 | 171.00 |
| | Correspond with client regarding filed Pow (0.6). | wer of Attorne | y and 3.73 Statement | |
| 12/03/20 | Sherrice Breland | 0.20 | P260 A105 | 57.00 |
| | Discuss Power of Attorney and 3.73 State | ment with B. F | lackman (0.2). | |

Firm Matter Number: 379612.165623

Client Name: Purdue Pharma L.P.

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 76 of 107

Invoice 1010003987 Page 3

Main Document

VALUES ON THIS INVOICE ARE BILLED IN USD

| DATE | TIMEKEEPER | Hours T | ASK | ACTIVITY | <u>Amount</u> |
|--------------|--|---------------------------|-------------|-----------------|---------------|
| 12/10/20 | Sherrice Breland | 0.20 | P260 | A103 | 57.00 |
| | Review file (0.1); download Notice of Reco (0.1). | ordation of A | ssignment | document | |
| 12/10/20 | Sherrice Breland | 0.70 | P260 | A106 | 199.50 |
| | Correspond with client regarding Notice o document (0.7). | f Recordatio | n of Assign | nment | |
| 12/10/20 | Sherrice Breland | 0.10 | P260 | A105 | 28.50 |
| | Discuss letter and Notice with B. Hackman | (0.1). | | | |
| 12/15/20 | Sherrice Breland | 0.60 | P260 | A103 | 171.00 |
| | Study Updated Filing Receipt newly receiv Trademark Office (0.1); study Notice of Ac received from U.S. Patent and Trademark correspondence and prosecution history (| ceptance of Office (0.1); | Applicatio | | |
| 12/15/20 | Sherrice Breland | 1.20 | P260 | A106 | 342.00 |
| | Correspondence with client regarding Filir client regarding Notice of Acceptance of A | | | pond with | |
| 12/15/20 | Sherrice Breland | 0.20 | P260 | A105 | 57.00 |
| | Discuss Updated Filing Receipt from U.S. PTO with B. Hackman (0.1); discuss and forward draft letter to B. Hackman regarding Notice of Acceptance of Application (0.1). | | | | |
| P260 SUBTOTA | AL HOURS AND FEES: | 7.30 | | | 2,201.00 |
| TOTAL HOURS | AND FEES | 7.30 | | | USD 2,201.00 |

| TITLE | D | | |
|-----------------|-----------------|------------------------|---|
| | <u>Rate</u> | <u>Hours</u> | AMOUNT |
| Associate | 740.00 | 0.30 | 222.00 |
| Legal Assistant | 285.00 | 6.60 | 1,881.00 |
| Legal Assistant | 245.00 | 0.40 | 98.00 |
| | | 7.30 | USD 2,201.00 |
| | Legal Assistant | Legal Assistant 285.00 | Legal Assistant 285.00 6.60 Legal Assistant 245.00 0.40 |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003987

Firm Client Matter Number: 379612.165623

Client Name: Purdue Pharma L.P.

Matter Name: (502US) (18-MT-0001US02) Sleep Disorder Treatment and Prevention

Electronic Billing Number: 20190002322

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 2,803.92

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003987) in the check memo. Mail to:

Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003988

Firm Client Matter Number: 379612.165625

Client Name: Purdue Pharma L.P.

Matter Name: (481US) (16-MT-0003US03) Treatment and Prevention of Sleep Disorders

Electronic Billing Number: 20190002321

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 142.50 |
|-------------------------------------|------------|
| Less 8% Discount | (11.40) |
| NET TOTAL FEES THIS INVOICE | 131.10 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 131 10 |
| TOTAL AIVIOUNT DOL FOR THIS INVOICE | |

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 79 of 107

Main Document

Invoice 1010003988 Page 2

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.165625

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL HOUR | RS AND FEES | 0.50 | | USD 142.50 |
|---------------|--|-------------------|-----------------|---------------|
| P260 SUBTO | TAL HOURS AND FEES: | 0.50 | | 142.50 |
| | Email with B. Hackman regarding ORL-1 documents (0.1). | related G. Senich | h working | |
| 12/15/20 | Sherrice Breland | 0.10 | P260 A105 | 28.50 |
| | Conduct searches for ORL-1 related G. Se | enich working do | ocuments (0.4). | |
| 12/15/20 | Sherrice Breland | 0.40 | P260 A102 | 114.00 |
| P260 - Intell | ectual Property | | | |
| <u>Date</u> | <u>TIMEKEEPER</u> | Hours Tas | <u>ACTIVITY</u> | <u>AMOUNT</u> |

| TIMEKEEPER SUMMARY: | | | | |
|---------------------|-----------------|--------------|-------|------------|
| TIMEKEEPER | TITLE | <u> Rате</u> | Hours | AMOUNT |
| S. Breland | Legal Assistant | 285.00 | 0.50 | 142.50 |
| TOTALS | | | 0.50 | USD 142.50 |
| | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003988

Firm Client Matter Number: 379612.165625

Client Name: Purdue Pharma L.P.

Matter Name: (481US) (16-MT-0003US03) Treatment and Prevention of Sleep Disorders

Electronic Billing Number: 20190002321

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 131.10

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003988) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003989

Firm Client Matter Number: 379612.168216

Client Name: Purdue Pharma L.P.

Matter Name: (478D1) (14-PS-0018US05) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002533

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 370.50 |
|-----------------------------------|------------|
| Less 8% Discount | (29.64) |
| NET TOTAL FEES THIS INVOICE | 340.86 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 340.86 |

Payment by Wire or ACH

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.168216

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 82 of 107

Main Document

Invoice 1010003989 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

| <u>Date</u> | TIMEKEEPER | Hours Task | ACTIVITY | <u>Amount</u> |
|----------------|---|---------------|-----------------|---------------|
| P260 – Intelle | ectual Property | | | |
| 12/04/20 | Sherrice Breland | 0.40 | P260 A104 | 114.00 |
| | Review letters patent (0.1); download is correspondence and prosecution history | • • • | organize | |
| 12/04/20 | Sherrice Breland | 0.70 | P260 A106 | 199.50 |
| | Prepare letter to client enclosing Letters | Patent (0.7). | | |
| 12/04/20 | Sherrice Breland | 0.20 | P260 A105 | 57.00 |
| | Communicate internally regarding draft | letter (0.2). | | |
| P260 SUBTO | TAL HOURS AND FEES: | 1.30 | | 370.50 |
| | _ | | | |
| TOTAL HOUR | S AND FEES | 1.30 | | USD 370.50 |
| | | | | |

| TIMEKEEPER SUMMARY: | | | | |
|---------------------|-----------------|--------|-------|------------|
| TIMEKEEPER | TITLE | RATE | Hours | AMOUNT |
| S. Breland | Legal Assistant | 285.00 | 1.30 | 370.50 |
| TOTALS | | | 1.30 | USD 370.50 |
| | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003989

Firm Client Matter Number: 379612.168216

Client Name: Purdue Pharma L.P.

Matter Name: (478D1) (14-PS-0018US05) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002533

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 340.86

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003989) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003990

Firm Client Matter Number: 379612.168318

Client Name: Purdue Pharma L.P.

Matter Name: (478D2) (14-PS-0018US06) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002534

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 370.50 |
|-----------------------------------|------------|
| Less 8% Discount | (29.64) |
| NET TOTAL FEES THIS INVOICE | 340.86 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 340.86 |

Payment by Wire or ACH

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 85 of 107

3/21 17:59:58 Main Document

Invoice 1010003990 Page 2

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.168318

VALUES ON THIS INVOICE ARE BILLED IN USD

| <u>Date</u> | TIMEKEEPER | Hours Ta | ASK ACTIVITY | <u>Amount</u> |
|---------------|---|--------------------|-------------------|---------------|
| P260 – Intell | ectual Property | | | |
| 12/10/20 | Sherrice Breland | 0.60 | P260 A103 | 171.00 |
| | Review file (0.1); review Issue Notificati and prosecution history (0.3). | on (0.2); organiz | ze correspondence | |
| 12/10/20 | Sherrice Breland | 0.70 | P260 A106 | 199.50 |
| | Prepare correspondence to client regar | ding Issue Notific | ication (0.7). | |
| P260 SUBTO | TAL HOURS AND FEES: | 1.30 | | 370.50 |
| | | | | |
| TOTAL HOUF | RS AND FEES | 1.30 | | USD 370.50 |
| | | | | |

| TIMEKEEPER SUMMARY: | | | | | | | |
|---------------------|-----------------|--------|-------|------------|--|--|--|
| TIMEKEEPER | TITLE | RATE | Hours | AMOUNT | | | |
| S. Breland | Legal Assistant | 285.00 | 1.30 | 370.50 | | | |
| TOTALS | | | 1.30 | USD 370.50 | | | |
| | | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003990

Firm Client Matter Number: 379612.168318

Client Name: Purdue Pharma L.P.

Matter Name: (478D2) (14-PS-0018US06) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002534

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 340.86

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003990) in the check memo. Mail to: Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003991

Firm Client Matter Number: 379612.174714

Client Name: Purdue Pharma L.P.

Matter Name: (484C6) (04-NC-0132US39) PROCESS FOR PREPARING OXYCODONE COMPOSITIONS

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 4,621.50 |
|-----------------------------------|--------------|
| Less 8% Discount | (369.72) |
| NET TOTAL FEES THIS INVOICE | 4,251.78 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 4,251.78 |

Payment by Wire or ACH

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.174714

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 88 of 107

Main Document

Invoice 1010003991 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

| DATE | TIMEKEEPER | Hours Tas | <u>sk</u> | ACTIVITY | <u>Amount</u> |
|----------------|--|-----------------|------------|-----------------|---------------|
| P260 – Intelle | ectual Property | | | | |
| 12/10/20 | Seth Snyder | 0.60 | P260 | A104 | 351.00 |
| | Review specification for support of new cla | aims (0.6). | | | |
| 12/10/20 | Seth Snyder | 0.90 | P260 | A103 | 526.50 |
| | Draft claims for new application (0.9). | | | | |
| 12/11/20 | Seth Snyder | 3.80 | P260 | A104 | 2,223.00 |
| | Review and revise claims for continuation specification for support of claims (0.7); pr (0.9); review related documents (0.8). | • • | • • | | |
| 12/15/20 | Seth Snyder | 0.30 | P260 | A104 | 175.50 |
| | Finalize claims for continuation application | n (0.3). | | | |
| 12/15/20 | Seth Snyder | 0.70 | P260 | A106 | 409.50 |
| | Draft letter to Purdue regarding continuati call with Purdue regarding same (0.2). | ion application | n (0.5); p | repare for | |
| 12/17/20 | Seth Snyder | 0.40 | P260 | A103 | 234.00 |
| | Draft preliminary amendment (0.4). | | | | |
| 12/17/20 | Seth Snyder | 1.20 | P260 | A106 | 702.00 |
| | Prepare for (0.4) and participate in meetin discuss draft claims (0.8). | g with Purdue | and S. A | Abrams to | |
| P260 SUBTO | TAL HOURS AND FEES: | 7.90 | | | 4,621.50 |
| TOTAL HOUF | ES AND FEES | 7.90 | | | USD 4,621.50 |
| | _ | | | | |

| TIMEKEEPER SUMMARY: | | | | | | | |
|---------------------|--------------|-------------|--------------|---------------|--|--|--|
| TIMEKEEPER | TITLE | <u>Rate</u> | <u>Hours</u> | <u>Amount</u> | | | |
| S. Snyder | Patent Agent | 585.00 | 7.90 | 4,621.50 | | | |
| TOTALS | | | 7.90 | USD 4,621.50 | | | |
| | | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003991

Firm Client Matter Number: 379612.174714

Client Name: Purdue Pharma L.P.

Matter Name: (484C6) (04-NC-0132US39) PROCESS FOR PREPARING OXYCODONE COMPOSITIONS

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 4,251.78

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003991) in the check memo. Mail to: Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003992

Firm Client Matter Number: 379612.174715

Client Name: Purdue Pharma L.P.

Matter Name: (484C5) (04-NC-0132US38) PROCESS FOR PREPARING OXYCODONE COMPOSITIONS

Electronic Billing Number: 20200002942

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 20 470 06 |
|-----------------------------------|---------------|
| TOTAL DISBURSEMENTS THIS INVOICE | 4,480.00 |
| NET TOTAL FEES THIS INVOICE | 15,990.06 |
| Less 8% Discount | (1,390.44) |
| TOTAL FEES THIS INVOICE | 17,380.50 |

Payment by Wire or ACH

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.174715 Invoice 1010003992 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

| DATE | TIMEKEEPER | Hours TA | <u>sk</u> | ACTIVITY | <u>Amount</u> |
|---------------|--|-----------------|------------|-----------------|---------------|
| P260 – Intell | ectual Property | | | | |
| 12/03/20 | Samuel Abrams | 1.80 | P260 | A104 | 1,593.00 |
| | Review proposed claims (1.8). | | | | |
| 12/03/20 | Samuel Abrams | 0.90 | P260 | A105 | 796.50 |
| | Call with Dr. Snyder regarding proposed cl | aims (.9). | | | |
| 12/03/20 | Seth Snyder | 0.40 | P260 | A104 | 234.00 |
| | Review claims (.4). | | | | |
| 12/03/20 | Seth Snyder | 0.90 | P260 | A105 | 526.50 |
| | Confer with S. Abrams regarding claiming a | and filing stra | tegies (.9 |). | |
| 12/04/20 | Samuel Abrams | 1.60 | P260 | A104 | 1,416.00 |
| | Review proposed claims (1.6). | | | | |
| 12/07/20 | Seth Snyder | 1.40 | P260 | A104 | 819.00 |
| | Review documents regarding continuation disclosures (.8). | application (| .6); revie | w scientific | |
| 12/07/20 | Seth Snyder | 0.80 | P260 | A103 | 468.00 |
| | Draft claims for continuation application (. | .8). | | | |
| 12/09/20 | Samuel Abrams | 2.00 | P260 | A103 | 1,770.00 |
| | Revise new claims. | | | | |
| 12/10/20 | Samuel Abrams | 1.70 | P260 | A104 | 1,504.50 |
| | Revise new claims (1.7). | | | | |
| 12/10/20 | Samuel Abrams | 0.80 | P260 | A105 | 708.00 |
| | Email with Dr. Snyder regarding new claim | ıs (.8). | | | |
| 12/11/20 | Samuel Abrams | 1.50 | P260 | A104 | 1,327.50 |
| | Review and analyze new proposed claims. | | | | |
| 12/14/20 | Samuel Abrams | 1.40 | P260 | A104 | 1,239.00 |
| | Review and revise claims (1.4). | | | | |
| 12/14/20 | Samuel Abrams | 0.60 | P260 | A105 | 531.00 |
| | Email with Dr. Snyder regarding claims (0.6 | 5). | | | |
| 12/17/20 | Samuel Abrams | 1.80 | P260 | A105 | 1,593.00 |
| | Prepare for (0.5) and teleconference with (0.6); follow-up with Dr. Snyder regarding | _ | ng propos | sed claims | |
| 12/18/20 | Seth Snyder | 1.70 | P260 | A103 | 994.50 |
| | Complete preliminary amendment and account with the USPTO. | companying d | locument | s for filing | |

Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 92 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.174715 Invoice 1010003992 Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

| <u>Date</u> | TIMEKEEPER | Hours Tas | <u>sk</u> | ACTIVITY | AMOUNT |
|-------------|---|------------------|------------|-----------------|---------------|
| 12/18/20 | Sherrice Breland | 0.90 | P260 | A103 | 256.50 |
| | Prepare draft Response to Notice to File corrected Application Data Sheet (0.2); of Time (0.1); review draft Preliminary A | prepare draft Pe | tition for | | |
| 12/18/20 | Sherrice Breland | 0.10 | P260 | A105 | 28.50 |
| | Email with S. Snyder regarding draft paper | | | | |
| 12/21/20 | Samuel Abrams | 0.60 | P260 | A104 | 531.00 |
| | Review preliminary amendment (1.6). | | | | |
| 12/21/20 | Samuel Abrams | 0.40 | P260 | A105 | 354.00 |
| | Email with Dr. Snyder regarding preliminary amendment (0.4). | | | | |
| 12/21/20 | Seth Snyder | 0.20 | P260 | A104 | 117.00 |
| | Review and file documents with the US | PTO. | | | |
| 12/21/20 | Sherrice Breland | 0.90 | P260 | A103 | 256.50 |
| | Study file (0.1); finalize Response to No Application Data Sheet and Petition for upload same with the U.S. PTO Filing Sy | Extension of Tim | _ | | |
| 12/21/20 | Sherrice Breland | 0.70 | P260 | A106 | 199.50 |
| | Prepare draft letter to client regarding to Missing Parts (0.2), corrected Application Extension of Time (0.3). | • | | | |
| 12/24/20 | Seth Snyder | 0.20 | P260 | A104 | 117.00 |
| | Study correspondence from USPTO. | | | | |
| P260 SUBTOT | AL HOURS AND FEES: | 23.30 | | | 17,380.50 |
| TOTAL HOURS | S AND FEES | 23.30 | | | USD 17,380.50 |

| TIMEKEEPER SUMMARY: | | | | | | |
|---------------------|-----------------|--------------|-------|---------------|--|--|
| TIMEKEEPER | <u>Title</u> | <u> Rate</u> | Hours | <u>Amount</u> | | |
| S. Abrams | Partner | 885.00 | 15.10 | 13,363.50 | | |
| S. Snyder | Patent Agent | 585.00 | 5.60 | 3,276.00 | | |
| S. Breland | Legal Assistant | 285.00 | 2.60 | 741.00 | | |
| TOTALS | | | 23.30 | USD 17,380.50 | | |
| | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003992

Firm Client Matter Number: 379612.174715

Client Name: Purdue Pharma L.P.

Matter Name: (484C5) (04-NC-0132US38) PROCESS FOR PREPARING OXYCODONE COMPOSITIONS

Electronic Billing Number: 20200002942

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 20,470.06

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003992) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003993

Firm Client Matter Number: 379612.177871

Client Name: Purdue Pharma L.P.

Matter Name: (506USP1) (20-MT-0001US01) Method of Treatment Using V117957 for Treating Interstitial Cystitis

Electronic Billing Number: 20200003038

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 11,694.00 |
|-----------------------------------|---------------|
| Less 8% Discount | (935.52) |
| NET TOTAL FEES THIS INVOICE | 10,758.48 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 10,758.48 |

Payment by Wire or ACH

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.177871

Main Document Pg 95 of 107

Invoice 1010003993 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

| <u>Date</u> | TIMEKEEPER | Hours TA | <u>sk</u> | ACTIVITY | <u>Amount</u> |
|---------------|--|-------------------|------------|-----------------|---------------|
| P260 - Intell | ectual Property | | | | |
| 12/03/20 | Samuel Abrams | 2.00 | P260 | A104 | 1,770.00 |
| | Review Purdue data regarding new application regarding same (1.4). | cation (0.6); rev | view pric | r art | |
| 12/03/20 | Sherrice Breland | 0.70 | P260 | A110 | 199.50 |
| | Review request for new provisional appli correspondence to PPLP regarding new porganize correspondence history (0.2). | | - | | |
| 12/04/20 | Samuel Abrams | 1.50 | P260 | A104 | 1,327.50 |
| | Review of prior art. | | | | |
| 12/04/20 | Seth Snyder | 3.50 | P260 | A104 | 2,047.50 |
| | Study disclosures from inventors (0.8); di review literature provided by inventors ((0.5); study references uncovered in sear | 1.0); perform p | | | |
| 12/07/20 | Samuel Abrams | 1.50 | P260 | A104 | 1,327.50 |
| | Continue review of prior art. | | | | |
| 12/07/20 | Seth Snyder | 1.40 | P260 | A104 | 819.00 |
| | Finalize studies provided by Purdue (0.5) finalize prior art searches (0.2); develop of | • | | | |
| 12/14/20 | Samuel Abrams | 0.50 | P260 | A101 | 442.50 |
| | Prepare for meeting regarding proposed | patent applicat | tion (0.5) |). | |
| 12/14/20 | Samuel Abrams | 0.50 | P260 | A105 | 442.50 |
| | Telecommunication with Dr. Snyder rega (0.5). | rding proposed | d patent | application | |
| 12/14/20 | Seth Snyder | 2.00 | P260 | A104 | 1,170.00 |
| | Develop claiming strategies (0.5); review conference with Purdue (0.7). | prior art (0.8); | prepare | for phone | |
| 12/14/20 | Seth Snyder | 0.50 | P260 | A105 | 292.50 |
| | Discuss claim strategies with S. Abrams (| 0.5). | | | |
| 12/15/20 | Samuel Abrams | 2.00 | P260 | A105 | 1,770.00 |
| | Prepare for (1.2) and teleconference with proposed patent application. | n Dechert team | (0.8) re | garding | |
| 12/16/20 | Sherrice Breland | 0.30 | P260 | A106 | 85.50 |
| | Review correspondence from client regard prepare communication to client regardi | | al applica | ation (0.1); | |
| P260 SUBTO | TAL HOURS AND FEES: | 16.40 | | | 11,694.00 |

19-23649-shl Doc 2412

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.177871 Filed 02/23/21 Entered 02/23/21 17:59:58

Main Document Pg 96 of 107

Invoice 1010003993 Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

| <u>Date</u> | TIMEKEEPER | Hours Task | <u>ACTIVITY</u> | AMOUNT |
|-------------|------------|------------|-----------------|---------------|
| TOTAL HOUR | S AND FEES | 16.40 | | USD 11,694.00 |

| TIMEKEEPER SUMMARY: | | | | | | |
|---------------------|-----------------|--------|-------|---------------|--|--|
| TIMEKEEPER | TITLE | RATE | Hours | AMOUNT | | |
| S. Abrams | Partner | 885.00 | 8.00 | 7,080.00 | | |
| S. Snyder | Patent Agent | 585.00 | 7.40 | 4,329.00 | | |
| S. Breland | Legal Assistant | 285.00 | 1.00 | 285.00 | | |
| TOTALS | | | 16.40 | USD 11,694.00 | | |
| | | | | | | |



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003993

Firm Client Matter Number: 379612.177871

Client Name: Purdue Pharma L.P.

Matter Name: (506USP1) (20-MT-0001US01) Method of Treatment Using V117957 for Treating Interstitial Cystitis

Electronic Billing Number: 20200003038

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 10,758.48

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003993) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003994

Firm Client Matter Number: 379612.177870

Client Name: Purdue Pharma L.P.

Matter Name: (505USP1) (19-MT-0001US01) Overactive Bladder - ORL 1 Inhibitors for OAC

Electronic Billing Number: 20200003037

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

| TOTAL FEES THIS INVOICE | 16,199.00 |
|-----------------------------------|---------------|
| Less 8% Discount | (1,295.92) |
| NET TOTAL FEES THIS INVOICE | 14,903.08 |
| TOTAL AMOUNT DUE FOR THIS INVOICE | USD 14,903.08 |

Payment by Wire or ACH

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.177870 Invoice 1010003994 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

| <u>Date</u> | TIMEKEEPER | Hours Ta | SK ACTIVITY | <u>Amount</u> |
|----------------|--|---------------|-----------------------|---------------|
| P260 – Intelle | ectual Property | | | |
| 12/03/20 | Blaine Hackman | 0.50 | P260 A104 | 370.00 |
| | Review prior art and pre-clinical information V'957 compound (0.5). | n on pre-clin | ical studies of the | |
| 12/03/20 | Blaine Hackman | 0.20 | P260 A105 | 148.00 |
| | Email with S. Abrams regarding the propose (0.2). | ed new provi | sional application | |
| 12/03/20 | Blaine Hackman | 0.30 | P260 A106 | 222.00 |
| | Correspond with W. Yang regarding the pro application (0.3). | posed new p | provisional | |
| 12/03/20 | Seth Snyder | 3.50 | P260 A104 | 2,047.50 |
| | Review disclosures from inventors (0.8); dra review literature provided by inventors (0.8 (0.9); review references uncovered in search |); perform p | | |
| 12/03/20 | Sherrice Breland | 0.50 | P260 A104 | 142.50 |
| | Review request for new provisional applicat correspondence to PPLP regarding new proorganize correspondence history (0.2). | | | |
| 12/03/20 | Sherrice Breland | 0.20 | P260 A105 | 57.00 |
| | Communicate internally regarding new provisional application (0.2). | | | |
| 12/04/20 | Blaine Hackman | 4.00 | P260 A104 | 2,960.00 |
| | Analyze pre-clinical data and prior art provious proposed provisional patent application. | ded by W. Ya | ing for drafting of a | |
| 12/07/20 | Blaine Hackman | 1.50 | P260 A104 | 1,110.00 |
| | Analyze the pre-clinical data and summary to matter for inclusion in a provisional application. | | otential subject | |
| 12/09/20 | Blaine Hackman | 1.80 | P260 A104 | 1,332.00 |
| | Analyze prior art references identified by Puinhibitors and the potential new indications | | chers relating ORL-1 | |
| 12/09/20 | Seth Snyder | 2.20 | P260 A104 | 1,287.00 |
| | Review references identified by Purdue (1.0 ORL-1 inhibitors for the treatment of urinar for inventors (0.6). | • • | | |
| 12/10/20 | Blaine Hackman | 1.00 | P260 A104 | 740.00 |
| | Analyze prior art references identified by Puinhibitors and the potential new indications in preparation for a call with W. Yang (0.5). | | _ | |

19-23649-shl Doc 2412

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.177870 Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 100 of 107

Main Document

Invoice 1010003994

Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

| EEPER Hackman w the clinical trial summaries provided in the clinical trial summaries provided in the clinical trial summaries provided in the clinical subject matter (1.1 No. Yang (0.3). Sinyder re for call with Purdue (0.3); finality (0.3); study pre-clinical data (0.7); sinyder with S. Abrams regarding strateging the clinical strate | 2.40 ze art searches (0 develop claiming | P260 and iden e confere P260 0.4); final | A104 lize review ies (0.7). | AMOUNT 1,036.00 1,404.00 |
|--|--|---|---|---|
| w the clinical trial summaries provitial patentable subject matter (1.1 V. Yang (0.3). Snyder re for call with Purdue (0.3); finalit (0.3); study pre-clinical data (0.7); Snyder with S. Abrams regarding strateging Hackman | ided by W. Yang 1); prepare for th 2.40 ze art searches (0 develop claiming 0.20 es (0.2). | and iden e conferce P260 0.4); final g strateg | A104 lize review ies (0.7). | ŕ |
| re for call with Purdue (0.3); finali (0.3); study pre-clinical data (0.7); Snyder with S. Abrams regarding strategic e Hackman | ze art searches (0 develop claimin 0.20 es (0.2). | 0.4); final g strateg | ize review ies (0.7). | 1,404.00 |
| (0.3); study pre-clinical data (0.7); Snyder with S. Abrams regarding strategic e Hackman | develop claiming 0.20 es (0.2). | g strateg | ies (0.7). | |
| with S. Abrams regarding strategice Hackman | es (0.2). | P260 | A105 | |
| e Hackman | | | | 117.00 |
| | 2.90 | | | |
| ze the prior art and scientific docu | | P260 | A104 | 2,146.00 |
| rence with S. Abrams regarding the rence with W. Yang regarding the ew indications. | e provisional pat | ent strat | egy; | |
| Snyder | 0.40 | P260 | A104 | 234.00 |
| w new disclosures (0.4). | | | | |
| Snyder | 0.20 | P260 | A105 | 117.00 |
| with S. Abrams regarding strategic | es (0.2). | | | |
| Snyder | 1.10 | P260 | A106 | 643.50 |
| re for (0.3) and participate in conf | erence call with | W. Yang | (0.8). | |
| ce Breland | 0.10 | P260 | A104 | 28.50 |
| w correspondence from client reg | arding new provi | isional ap | plication | |
| ce Breland | 0.20 | P260 | A105 | 57.00 |
| nunicate with Dechert team regard | ding new provision | onal appl | ication (0.2). | |
| IRS AND FEES: | 24.60 | | | 16,199.00 |
| | | | | |
| _ | | | | |
| , i | with S. Abrams regarding strateging of the strat | with S. Abrams regarding strategies (0.2). nyder re for (0.3) and participate in conference call with ce Breland v correspondence from client regarding new provi ce Breland 0.20 nunicate with Dechert team regarding new provision | with S. Abrams regarding strategies (0.2). nyder 1.10 P260 re for (0.3) and participate in conference call with W. Yang ce Breland 0.10 P260 v correspondence from client regarding new provisional ap ce Breland 0.20 P260 nunicate with Dechert team regarding new provisional appl | with S. Abrams regarding strategies (0.2). nyder 1.10 P260 A106 re for (0.3) and participate in conference call with W. Yang (0.8). ce Breland 0.10 P260 A104 v correspondence from client regarding new provisional application ce Breland 0.20 P260 A105 nunicate with Dechert team regarding new provisional application (0.2). |

19-23649-shl Doc 2412

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.177870

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 101 of 107

21 17:59:58 Main Document

Invoice 1010003994 Page 4

VALUES ON THIS INVOICE ARE BILLED IN USD

| TIMEKEEPER SUMMARY: | | | | |
|---------------------|-----------------|--------------|--------------|---------------|
| TIMEKEEPER | <u>Title</u> | <u> Rате</u> | Hours | AMOUNT |
| B. Hackman | Associate | 740.00 | 13.60 | 10,064.00 |
| S. Snyder | Patent Agent | 585.00 | 10.00 | 5,850.00 |
| S. Breland | Legal Assistant | 285.00 | 1.00 | 285.00 |
| TOTALS | | | 24.60 | USD 16,199.00 |



REMITTANCE AND PAYMENT INSTRUCTIONS

For guestions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 23, 2021 Invoice Number 1010003994

Firm Client Matter Number: 379612.177870

Client Name: Purdue Pharma L.P.

Matter Name: (505USP1) (19-MT-0001US01) Overactive Bladder - ORL 1 Inhibitors for OAC

Electronic Billing Number: 20200003037

Professional Services Rendered Through December 31, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 14,903.08

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003994) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643

19-23649-shl Doc 2412 Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 103 of 107

EXHIBIT B

Expenses

19-23649-shl Doc 2412 Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 104 of 107

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003983 Page 41

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

| DESCRIPTION | <u>Amount</u> |
|---|---------------|
| Court Costs | |
| Court Costs - Telephonic appearance at Dec. 15 hearing - 12/15/2020 | 70.00 |
| Court Costs - Telephonic appearance at Dec. 15 hearing - 12/15/2020 | 70.00 |
| Court Costs - Telephonic appearance at Dec. 15 hearing - 12/15/2020 | 70.00 |
| | 210.00 |
| Taxi Fare | |
| Taxi Fare - VENDOR: Elite Car Service 10/30/2020 Coleman 176 BROADWAY | 41.38 |
| | 41.38 |
| TOTAL DISBURSEMENTS | USD 251.38 |

19-23649-shl Doc 2412

Firm Matter Number: 379612.174715

Client Name: Purdue Pharma L.P.

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 105 of 107

Main Document

Invoice 1010003992 Page 4

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

| DESCRIPTION | <u>AMOUNT</u> |
|---|---------------|
| Filing Fees and Related | |
| Filing Fees and Related - VENDOR: U.S. Patent and Trademark UTILITY PATENT APPL. | 700.00 |
| SEARCH FEE | |
| Filing Fees and Related - VENDOR: U.S. Patent and Trademark PATENT APPL. EXAMINATION FEE | 800.00 |
| Filing Fees and Related - VENDOR: U.S. Patent and Trademark EACH CLAIM IN EXCESS OF 20 | 500.00 |
| Filing Fees and Related - VENDOR: U.S. Patent and Trademark SURCHARGE- LATE FILING FEE, SEARCH FEE, EXAMINATION FEE, INVENTOR'S OATH OR DEC | 160.00 |
| Filing Fees and Related - VENDOR: U.S. Patent and Trademark EXTENSION FOR RESPONSE W/IN FOURTH MONTH | 2,320.00 |
| | 4,480.00 |
| TOTAL DISBURSEMENTS | USD 4,480.00 |
| | |

19-23649-shl Doc 2412

Filed 02/23/21 Entered 02/23/21 17:59:58 Pg 106 of 107

9:58 Main Document

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.165623 Invoice 1010003987 Page 4

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

| DESCRIPTION | <u>AMOUNT</u> |
|---|---------------|
| Filing Fees and Related Filing Fees and Related - VENDOR: U.S. Patent and Trademark SEARCH FEE, EXAMINATION FEE OR OATH OR DECLARATION AFTER THE DATE OF COMMENCEMENT OF THE NATIONAL | 160.00 |
| STAGE Filing Fees and Related - VENDOR: U.S. Patent and Trademark EXTENSION FOR RESPONSE WITHIN SECOND MO | 619.00 |
| | 779.00 |
| TOTAL DISBURSEMENTS | USD 779.00 |

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.156278

19-23649-shl Doc 2412 Filed 02/23/21 Entered 02/23/21 17:59:58 Main Document Pg 107 of 107

Invoice 1010003986 Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

DESCRIPTION AMOUNT **Filing Fees and Related** Filing Fees and Related - VENDOR: U.S. Patent and Trademark SUBMISSION OF AN 260.00 INFORMATION DISCLOSURE STATEMENT 260.00 **TOTAL DISBURSEMENTS** USD 260.00